{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:45:24Z","timestamp":1791762324386,"version":"4.3.4"},"reference-count":494,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02840-z","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:01:57Z","timestamp":1791759717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics"],"prefix":"10.1038","volume":"11","author":[{"given":"Kai","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6742-7074","authenticated-orcid":false,"given":"Hangping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2840_CR1","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.1016\/S0021-9258(18)43497-7","volume":"255","author":"H Ushiro","year":"1980","unstructured":"Ushiro, H. & Cohen, S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 255, 8363\u20138365 (1980).","journal-title":"J. Biol. Chem."},{"key":"2840_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/298667a0","volume":"298","author":"M Kasuga","year":"1982","unstructured":"Kasuga, M., Zick, Y., Blithe, D. L., Crettaz, M. & Kahn, C. R. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system. Nature 298, 667\u2013669 (1982).","journal-title":"Nature"},{"key":"2840_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/295419a0","volume":"295","author":"B Ek","year":"1982","unstructured":"Ek, B., Westermark, B., Wasteson, A. & Heldin, C. H. Stimulation of tyrosine-specific phosphorylation by platelet-derived growth factor. Nature 295, 419\u2013420 (1982).","journal-title":"Nature"},{"key":"2840_CR4","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1242\/dev.033597","volume":"136","author":"M Jeon","year":"2009","unstructured":"Jeon, M. & Zinn, K. Receptor tyrosine phosphatases control tracheal tube geometries through negative regulation of Egfr signaling. Development 136, 3121\u20133129 (2009).","journal-title":"Development"},{"key":"2840_CR5","doi-asserted-by":"publisher","first-page":"6554","DOI":"10.1073\/pnas.0506886103","volume":"103","author":"LD Covassin","year":"2006","unstructured":"Covassin, L. D., Villefranc, J. A., Kacergis, M. C., Weinstein, B. M. & Lawson, N. D. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc. Natl. Acad. Sci. USA 103, 6554\u20136559 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2840_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/348693a0","volume":"348","author":"RV Aroian","year":"1990","unstructured":"Aroian, R. V., Koga, M., Mendel, J. E., Ohshima, Y. & Sternberg, P. W. The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. Nature 348, 693\u2013699 (1990).","journal-title":"Nature"},{"key":"2840_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/sj.emboj.7600460","volume":"24","author":"MN Chamorro","year":"2005","unstructured":"Chamorro, M. N. et al. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 24, 73\u201384 (2005).","journal-title":"EMBO J"},{"key":"2840_CR8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117\u20131134 (2010).","journal-title":"Cell"},{"key":"2840_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du, Z. & Lovly, C. M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 17, 58 (2018).","journal-title":"Mol. Cancer"},{"key":"2840_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2840_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41571-023-00813-7","volume":"20","author":"D DeRyckere","year":"2023","unstructured":"DeRyckere, D., Huelse, J. M., Earp, H. S. & Graham, D. K. TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nat. Rev. Clin. Oncol. 20, 755\u2013779 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2840_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa, C. et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct. Target Ther. 9, 201 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2840_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","volume":"80","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi, N. et al. Receptor tyrosine kinase inhibitors in cancer. Cell. Mol. Life Sci. 80, 104 (2023).","journal-title":"Cell. Mol. Life Sci."},{"key":"2840_CR14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1161\/CIRCRESAHA.124.325880","volume":"136","author":"X Gai","year":"2025","unstructured":"Gai, X. et al. GOLM1 PromOtes Atherogenesis By Activating Macrophage EGFR-ERK signaling cascade. Circ. Res. 136, 848\u2013861 (2025).","journal-title":"Circ. Res."},{"key":"2840_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/med.22075","volume":"45","author":"M Antonijevic","year":"2025","unstructured":"Antonijevic, M., Dallemagne, P. & Rochais, C. Indirect influence on the BDNF\/TrkB receptor signaling pathway via GPCRs, an emerging strategy in the treatment of neurodegenerative disorders. Med. Res. Rev. 45, 274\u2013310 (2025).","journal-title":"Med. Res. Rev."},{"key":"2840_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.apsb.2024.01.013","volume":"14","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Hyperglycemia activates FGFR1 via TLR4\/c-Src pathway to induce inflammatory cardiomyopathy in diabetes. Acta Pharm. Sin. B 14, 1693\u20131710 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"2840_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/S0021-9258(19)83739-0","volume":"237","author":"S Cohen","year":"1962","unstructured":"Cohen, S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem. 237, 1555\u20131562 (1962).","journal-title":"J. Biol. Chem."},{"key":"2840_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1083\/jcb.71.1.159","volume":"71","author":"G Carpenter","year":"1976","unstructured":"Carpenter, G. & Cohen, S. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J. Cell Biol. 71, 159\u2013171 (1976).","journal-title":"J. Cell Biol."},{"key":"2840_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/309418a0","volume":"309","author":"A Ullrich","year":"1984","unstructured":"Ullrich, A. et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418\u2013425 (1984).","journal-title":"Nature"},{"key":"2840_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/312513a0","volume":"312","author":"AL Schechter","year":"1984","unstructured":"Schechter, A. L. et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312, 513\u2013516 (1984).","journal-title":"Nature"},{"key":"2840_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"2840_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/CIRCRESAHA.109.207357","volume":"105","author":"C Franco","year":"2009","unstructured":"Franco, C. et al. Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis. Circ. Res. 105, 1141\u20131148 (2009).","journal-title":"Circ. Res."},{"key":"2840_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0308-0","volume":"16","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation. Cell Commun. Signal. 16, 98 (2018).","journal-title":"Cell Commun. Signal."},{"key":"2840_CR24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1097\/HEP.0000000000000319","volume":"78","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-\u03b2\/SMAD signaling. Hepatology 78, 1433\u20131447 (2023).","journal-title":"Hepatology"},{"key":"2840_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.emboj.7600912","volume":"25","author":"T Sasaki","year":"2006","unstructured":"Sasaki, T. et al. Structural basis for Gas6-Axl signalling. EMBO J 25, 80\u201387 (2006).","journal-title":"EMBO J"},{"key":"2840_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0092-8674(00)80456-0","volume":"91","author":"C Wiesmann","year":"1997","unstructured":"Wiesmann, C. et al. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695\u2013704 (1997).","journal-title":"Cell"},{"key":"2840_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nsmb1101","volume":"13","author":"WA Barton","year":"2006","unstructured":"Barton, W. A. et al. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat. Struct. Mol. Biol. 13, 524\u2013532 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2840_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu, Q., Qian, W., Sun, X. & Jiang, S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J. Hematol. Oncol. 15, 143 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2840_CR29","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","volume":"19","author":"HJ Burstein","year":"2001","unstructured":"Burstein, H. J. et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 19, 2722\u20132730 (2001).","journal-title":"J. Clin. Oncol."},{"key":"2840_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","volume":"8","author":"MH Cohen","year":"2003","unstructured":"Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G. & Pazdur, R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8, 303\u2013306 (2003).","journal-title":"Oncologist"},{"key":"2840_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","volume":"38","author":"V Noronha","year":"2020","unstructured":"Noronha, V. et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J. Clin. Oncol. 38, 124\u2013136 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2840_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EW Ng","year":"2006","unstructured":"Ng, E. W. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123\u2013132 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2840_CR33","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas, E. S., Adamis, A. P., Cunningham, E. T. Jr., Feinsod, M. & Guyer, D. R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805\u20132816 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Li, S., Wang, Y., Zhao, Y. & Li, Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct. Target Ther. 7, 329 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2840_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790. Mater. Nat. Med. 21, 560\u2013562 (2015).","journal-title":"Mater. Nat. Med."},{"key":"2840_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104850","volume":"9","author":"B Ma","year":"2022","unstructured":"Ma, B. et al. Kill two birds with one stone: a multifunctional dual-targeting protein drug to overcome imatinib resistance in Philadelphia chromosome-positive leukemia. Adv. Sci. 9, e2104850 (2022).","journal-title":"Adv. Sci."},{"key":"2840_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0778-0","volume":"17","author":"CS Tan","year":"2018","unstructured":"Tan, C. S. et al. Third-generation EGFR TKIs: current data and future directions. Mol. Cancer 17, 29 (2018).","journal-title":"Mol. Cancer"},{"key":"2840_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-019-0768-8","volume":"12","author":"B George","year":"2019","unstructured":"George, B. et al. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma. J. Hematol. Oncol. 12, 80 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2840_CR39","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912\u20131934 (2002).","journal-title":"Science"},{"key":"2840_CR40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.tcb.2006.07.003","volume":"16","author":"J Boudeau","year":"2006","unstructured":"Boudeau, J., Miranda-Saavedra, D., Barton, G. J. & Alessi, D. R. Emerging roles of pseudokinases. Trends Cell Biol. 16, 443\u2013452 (2006).","journal-title":"Trends Cell Biol."},{"key":"2840_CR41","doi-asserted-by":"publisher","first-page":"6427","DOI":"10.1128\/MCB.19.9.6427","volume":"19","author":"RM Katso","year":"1999","unstructured":"Katso, R. M., Russell, R. B. & Ganesan, T. S. Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family. Mol. Cell. Biol. 19, 6427\u20136440 (1999).","journal-title":"Mol. Cell. Biol."},{"key":"2840_CR42","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-10-2662","volume":"71","author":"A Gentile","year":"2011","unstructured":"Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L. & Comoglio, P. M. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71, 3132\u20133141 (2011).","journal-title":"Cancer Res."},{"key":"2840_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","volume":"150","author":"Z Debebe","year":"2015","unstructured":"Debebe, Z. & Rathmell, W. K. Ror2 as a therapeutic target in cancer. Pharmacol. Ther. 150, 143\u2013148 (2015).","journal-title":"Pharmacol. Ther."},{"key":"2840_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-019-0018-3","volume":"18","author":"JE Kung","year":"2019","unstructured":"Kung, J. E. & Jura, N. Prospects for pharmacological targeting of pseudokinases. Nat. Rev. Drug Discov. 18, 501\u2013526 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2840_CR45","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/molbev\/mst241","volume":"31","author":"H Suga","year":"2014","unstructured":"Suga, H., Torruella, G., Burger, G., Brown, M. W. & Ruiz-Trillo, I. Earliest holozoan expansion of phosphotyrosine signaling. Mol. Biol. Evol. 31, 517\u2013528 (2014).","journal-title":"Mol. Biol. Evol."},{"key":"2840_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1097-2765(00)80004-0","volume":"1","author":"A Shrivastava","year":"1997","unstructured":"Shrivastava, A. et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol. Cell 1, 25\u201334 (1997).","journal-title":"Mol. Cell"},{"key":"2840_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03168-4","volume":"14","author":"D Rasool","year":"2024","unstructured":"Rasool, D. & Jahani-Asl, A. Master regulators of neurogenesis: the dynamic roles of Ephrin receptors across diverse cellular niches. Transl. Psychiatry 14, 462 (2024).","journal-title":"Transl. Psychiatry"},{"key":"2840_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","volume":"24","author":"EB Pasquale","year":"2024","unstructured":"Pasquale, E. B. Eph receptors and ephrins in cancer progression. Nat. Rev. Cancer 24, 5\u201327 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1748-1716.2007.01781.x","volume":"192","author":"C Ward","year":"2008","unstructured":"Ward, C. et al. Structural insights into ligand-induced activation of the insulin receptor. Acta Physiol. 192, 3\u20139 (2008).","journal-title":"Acta Physiol."},{"key":"2840_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0166-2236(02)00005-X","volume":"26","author":"JP Himanen","year":"2003","unstructured":"Himanen, J. P. & Nikolov, D. B. Eph signaling: a structural view. Trends Neurosci. 26, 46\u201351 (2003).","journal-title":"Trends Neurosci."},{"key":"2840_CR51","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nature08827","volume":"464","author":"I Chung","year":"2010","unstructured":"Chung, I. et al. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 464, 783\u2013787 (2010).","journal-title":"Nature"},{"key":"2840_CR52","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1042\/bj2900419","volume":"290","author":"MA Soos","year":"1993","unstructured":"Soos, M. A., Field, C. E. & Siddle, K. Purified hybrid insulin\/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem. J. 290, 419\u2013426 (1993).","journal-title":"Biochem. J."},{"key":"2840_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","volume":"109","author":"M Huse","year":"2002","unstructured":"Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275\u2013282 (2002).","journal-title":"Cell"},{"key":"2840_CR54","doi-asserted-by":"publisher","first-page":"46265","DOI":"10.1074\/jbc.M207135200","volume":"277","author":"J Stamos","year":"2002","unstructured":"Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265\u201346272 (2002).","journal-title":"J. Biol. Chem."},{"key":"2840_CR55","doi-asserted-by":"publisher","first-page":"31461","DOI":"10.1074\/jbc.C300186200","volume":"278","author":"CD Mol","year":"2003","unstructured":"Mol, C. D. et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278, 31461\u201331464 (2003).","journal-title":"J. Biol. Chem."},{"key":"2840_CR56","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/nsb721","volume":"8","author":"S Favelyukis","year":"2001","unstructured":"Favelyukis, S., Till, J. H., Hubbard, S. R. & Miller, W. T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 8, 1058\u20131063 (2001).","journal-title":"Nat. Struct. Biol."},{"key":"2840_CR57","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1093\/emboj\/16.18.5572","volume":"16","author":"SR Hubbard","year":"1997","unstructured":"Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572\u20135581 (1997).","journal-title":"EMBO J."},{"key":"2840_CR58","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0969-2126(99)80042-2","volume":"7","author":"MA McTigue","year":"1999","unstructured":"McTigue, M. A. et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7, 319\u2013330 (1999).","journal-title":"Structure"},{"key":"2840_CR59","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","volume":"15","author":"B Nolen","year":"2004","unstructured":"Nolen, B., Taylor, S. & Ghosh, G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15, 661\u2013675 (2004).","journal-title":"Mol. Cell"},{"key":"2840_CR60","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cell.2009.05.028","volume":"138","author":"JH Bae","year":"2009","unstructured":"Bae, J. H. et al. The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell 138, 514\u2013524 (2009).","journal-title":"Cell"},{"key":"2840_CR61","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","volume":"27","author":"H Chen","year":"2007","unstructured":"Chen, H. et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717\u2013730 (2007).","journal-title":"Mol. Cell"},{"key":"2840_CR62","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrm1399","volume":"5","author":"SR Hubbard","year":"2004","unstructured":"Hubbard, S. R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 464\u2013470 (2004).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2840_CR63","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0092-8674(01)00496-2","volume":"106","author":"LE Wybenga-Groot","year":"2001","unstructured":"Wybenga-Groot, L. E. et al. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106, 745\u2013757 (2001).","journal-title":"Cell"},{"key":"2840_CR64","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1073\/pnas.0305363101","volume":"101","author":"Y Kimura","year":"2004","unstructured":"Kimura, Y. et al. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc. Natl. Acad. Sci. USA 101, 6015\u20136020 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2840_CR65","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1182\/blood-2005-07-008896","volume":"108","author":"E Heiss","year":"2006","unstructured":"Heiss, E. et al. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood 108, 1542\u20131550 (2006).","journal-title":"Blood"},{"key":"2840_CR66","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbrc.2016.06.117","volume":"477","author":"L Liang","year":"2016","unstructured":"Liang, L., Yan, X. E., Yin, Y. & Yun, C. H. Structural and biochemical studies of the PDGFRA kinase domain. Biochem. Biophys. Res. Commun. 477, 667\u2013672 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2840_CR67","doi-asserted-by":"publisher","first-page":"31768","DOI":"10.1074\/jbc.M203995200","volume":"277","author":"XL Niu","year":"2002","unstructured":"Niu, X. L., Peters, K. G. & Kontos, C. D. Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function: evidence for an autoinhibitory mechanism. J. Biol. Chem. 277, 31768\u201331773 (2002).","journal-title":"J. Biol. Chem."},{"key":"2840_CR68","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0969-2126(00)00516-5","volume":"8","author":"LM Shewchuk","year":"2000","unstructured":"Shewchuk, L. M. et al. Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 8, 1105\u20131113 (2000).","journal-title":"Structure"},{"key":"2840_CR69","doi-asserted-by":"publisher","first-page":"8893","DOI":"10.1074\/jbc.M412623200","volume":"280","author":"N Yokoyama","year":"2005","unstructured":"Yokoyama, N., Ischenko, I., Hayman, M. J. & Miller, W. T. The C terminus of RON tyrosine kinase plays an autoinhibitory role. J. Biol. Chem. 280, 8893\u20138900 (2005).","journal-title":"J. Biol. Chem."},{"key":"2840_CR70","doi-asserted-by":"publisher","first-page":"19732","DOI":"10.1074\/jbc.M314070200","volume":"279","author":"F Chiara","year":"2004","unstructured":"Chiara, F., Bishayee, S., Heldin, C. H. & Demoulin, J. B. Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail. J. Biol. Chem. 279, 19732\u201319738 (2004).","journal-title":"J. Biol. Chem."},{"key":"2840_CR71","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","volume":"125","author":"X Zhang","year":"2006","unstructured":"Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137\u20131149 (2006).","journal-title":"Cell"},{"key":"2840_CR72","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"MJ Wieduwilt","year":"2008","unstructured":"Wieduwilt, M. J. & Moasser, M. M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 65, 1566\u20131584 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"2840_CR73","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1535-6108(02)00076-4","volume":"1","author":"KL Carraway 3rd","year":"2002","unstructured":"Carraway, K. L. 3rd & Sweeney, C. EGF receptor activation by heterologous mechanisms. Cancer Cell 1, 405\u2013406 (2002).","journal-title":"Cancer Cell"},{"key":"2840_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol. Cancer 17, 45 (2018).","journal-title":"Mol. Cancer"},{"key":"2840_CR75","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrc3545","volume":"13","author":"HP Yao","year":"2013","unstructured":"Yao, H. P., Zhou, Y. Q., Zhang, R. & Wang, M. H. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat. Rev. Cancer 13, 466\u2013481 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR76","first-page":"100050","volume":"1","author":"BE Osta","year":"2020","unstructured":"Osta, B. E. & Ramalingam, S. S. RET fusion: joining the ranks of targetable molecular drivers in NSCLC. JTO Clin. Res. Rep. 1, 100050 (2020).","journal-title":"JTO Clin. Res. Rep."},{"key":"2840_CR77","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.canlet.2007.08.007","volume":"257","author":"Y Lu","year":"2007","unstructured":"Lu, Y., Yao, H. P. & Wang, M. H. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 257, 157\u2013164 (2007).","journal-title":"Cancer Lett."},{"key":"2840_CR78","doi-asserted-by":"publisher","first-page":"130470","DOI":"10.1016\/j.bbagen.2023.130470","volume":"1867","author":"M Domenichini","year":"2023","unstructured":"Domenichini, M. et al. The D647N mutation of FGFR1 induces ligand-independent receptor activation. Biochim. Biophys. Acta Gen. Subj. 1867, 130470 (2023).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"2840_CR79","doi-asserted-by":"publisher","first-page":"E8162","DOI":"10.1073\/pnas.1803152115","volume":"115","author":"Z Ruan","year":"2018","unstructured":"Ruan, Z. & Kannan, N. Altered conformational landscape and dimerization dependency underpins the activation of EGFR by \u03b1C-\u03b24 loop insertion mutations. Proc. Natl. Acad. Sci. USA 115, E8162\u2013E8171 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2840_CR80","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1097-2765(05)00087-0","volume":"6","author":"C Dhalluin","year":"2000","unstructured":"Dhalluin, C. et al. Structural basis of SNT PTB domain interactions with distinct neurotrophic receptors. Mol. Cell 6, 921\u2013929 (2000).","journal-title":"Mol. Cell"},{"key":"2840_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06823-9","volume":"9","author":"JR LaRochelle","year":"2018","unstructured":"LaRochelle, J. R. et al. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nat. Commun. 9, 4508 (2018).","journal-title":"Nat. Commun."},{"key":"2840_CR82","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.7150\/thno.72269","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis. Theranostics 12, 4513\u20134535 (2022).","journal-title":"Theranostics"},{"key":"2840_CR83","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrm1837","volume":"7","author":"CM Taniguchi","year":"2006","unstructured":"Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85\u201396 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2840_CR84","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/sj.onc.1202422","volume":"18","author":"AM Tari","year":"1999","unstructured":"Tari, A. M., Hung, M. C., Li, K. & Lopez-Berestein, G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 18, 1325\u20131332 (1999).","journal-title":"Oncogene"},{"key":"2840_CR85","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.molcel.2012.06.037","volume":"47","author":"Z Yang","year":"2012","unstructured":"Yang, Z. et al. The signaling adaptor GAB1 regulates cell polarity by acting as a PAR protein scaffold. Mol. Cell 47, 469\u2013483 (2012).","journal-title":"Mol. Cell"},{"key":"2840_CR86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161472","volume":"133","author":"H Nagao","year":"2023","unstructured":"Nagao, H. et al. Leucine-973 is a crucial residue differentiating insulin and IGF-1 receptor signaling. J. Clin. Investig. 133, e161472 (2023).","journal-title":"J. Clin. Investig."},{"key":"2840_CR87","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cels.2022.10.003","volume":"13","author":"AF Peterson","year":"2022","unstructured":"Peterson, A. F. et al. Systematic analysis of the MAPK signaling network reveals MAP3K-driven control of cell fate. Cell Syst. 13, 885\u2013894.e884 (2022).","journal-title":"Cell Syst."},{"key":"2840_CR88","doi-asserted-by":"publisher","first-page":"2005.0010","DOI":"10.1038\/msb4100014","volume":"1","author":"K Oda","year":"2005","unstructured":"Oda, K., Matsuoka, Y., Funahashi, A. & Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1, 2005.0010 (2005).","journal-title":"Mol. Syst. Biol."},{"key":"2840_CR89","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0092-8674(00)80252-4","volume":"89","author":"H Kouhara","year":"1997","unstructured":"Kouhara, H. et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras\/MAPK signaling pathway. Cell 89, 693\u2013702 (1997).","journal-title":"Cell"},{"key":"2840_CR90","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41580-025-00826-3","volume":"26","author":"E Choi","year":"2025","unstructured":"Choi, E., Duan, C. & Bai, X. C. Regulation and function of insulin and insulin-like growth factor receptor signalling. Nat. Rev. Mol. Cell Biol. 26, 558\u2013580 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2840_CR91","doi-asserted-by":"publisher","first-page":"a009043","DOI":"10.1101\/cshperspect.a009043","volume":"5","author":"N Volinsky","year":"2013","unstructured":"Volinsky, N. & Kholodenko, B. N. Complexity of receptor tyrosine kinase signal processing. Cold Spring Harb. Perspect. Biol. 5, a009043 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2840_CR92","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-021-01137-8","volume":"14","author":"H Hua","year":"2021","unstructured":"Hua, H. et al. Targeting Akt in cancer for precision therapy. J. Hematol. Oncol. 14, 128 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2840_CR93","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7\u201324 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR94","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/35074604","volume":"3","author":"H Miao","year":"2001","unstructured":"Miao, H. et al. Activation of EphA receptor tyrosine kinase inhibits the Ras\/MAPK pathway. Nat. Cell Biol. 3, 527\u2013530 (2001).","journal-title":"Nat. Cell Biol."},{"key":"2840_CR95","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","volume":"16","author":"H Miao","year":"2009","unstructured":"Miao, H. et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9\u201320 (2009).","journal-title":"Cancer Cell"},{"key":"2840_CR96","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccr.2005.07.005","volume":"8","author":"M Macrae","year":"2005","unstructured":"Macrae, M. et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8, 111\u2013118 (2005).","journal-title":"Cancer Cell"},{"key":"2840_CR97","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cellsig.2010.09.004","volume":"23","author":"NY Yang","year":"2011","unstructured":"Yang, N. Y. et al. Crosstalk of the EphA2 receptor with a serine\/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell. Signal. 23, 201\u2013212 (2011).","journal-title":"Cell. Signal."},{"key":"2840_CR98","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/j.1460-2075.1994.tb06421.x","volume":"13","author":"A Obermeier","year":"1994","unstructured":"Obermeier, A. et al. Neuronal differentiation signals are controlled by nerve growth factor receptor\/Trk binding sites for SHC and PLC\u03b3. EMBO J. 13, 1585\u20131590 (1994).","journal-title":"EMBO J."},{"key":"2840_CR99","doi-asserted-by":"publisher","first-page":"188619","DOI":"10.1016\/j.bbcan.2021.188619","volume":"1876","author":"S Mandal","year":"2021","unstructured":"Mandal, S., Bandyopadhyay, S., Tyagi, K. & Roy, A. Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis. Biochim. Biophys. Acta Rev. Cancer 1876, 188619 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2840_CR100","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abc6612","volume":"14","author":"D Chen","year":"2021","unstructured":"Chen, D. & Simons, M. Emerging roles of PLC\u03b31 in endothelial biology. Sci. Signal. 14, eabc6612 (2021).","journal-title":"Sci. Signal."},{"key":"2840_CR101","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1038\/sj.emboj.7600399","volume":"23","author":"DL Medina","year":"2004","unstructured":"Medina, D. L. et al. TrkB regulates neocortex formation through the Shc\/PLCgamma-mediated control of neuronal migration. EMBO J. 23, 3803\u20133814 (2004).","journal-title":"EMBO J."},{"key":"2840_CR102","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea, J. J., Holland, S. M. & Staudt, L. M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368, 161\u2013170 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR103","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi, E., Birchmeier, W., Birchmeier, C. & Vande Woude, G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89\u2013103 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR104","first-page":"3923","volume":"63","author":"H Shao","year":"2003","unstructured":"Shao, H., Cheng, H. Y., Cook, R. G. & Tweardy, D. J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63, 3923\u20133930 (2003).","journal-title":"Cancer Res"},{"key":"2840_CR105","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.oraloncology.2015.03.004","volume":"51","author":"SB Mali","year":"2015","unstructured":"Mali, S. B. Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer. Oral Oncol. 51, 565\u2013569 (2015).","journal-title":"Oral Oncol."},{"key":"2840_CR106","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi, K. & Karin, M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309\u2013324 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2840_CR107","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.canlet.2017.09.047","volume":"411","author":"SK Tey","year":"2017","unstructured":"Tey, S. K. et al. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-\u03baB pathway. Cancer Lett. 411, 150\u2013161 (2017).","journal-title":"Cancer Lett."},{"key":"2840_CR108","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/43466","volume":"401","author":"ON Ozes","year":"1999","unstructured":"Ozes, O. N. et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82\u201385 (1999).","journal-title":"Nature"},{"key":"2840_CR109","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/43474","volume":"401","author":"JA Romashkova","year":"1999","unstructured":"Romashkova, J. A. & Makarov, S. S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86\u201390 (1999).","journal-title":"Nature"},{"key":"2840_CR110","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cellsig.2009.10.006","volume":"22","author":"A Salminen","year":"2010","unstructured":"Salminen, A. & Kaarniranta, K. Insulin\/IGF-1 paradox of aging: regulation via AKT\/IKK\/NF-kappaB signaling. Cell. Signal. 22, 573\u2013577 (2010).","journal-title":"Cell. Signal."},{"key":"2840_CR111","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1101\/gad.1662308","volume":"22","author":"HC Dan","year":"2008","unstructured":"Dan, H. C. et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22, 1490\u20131500 (2008).","journal-title":"Genes Dev"},{"key":"2840_CR112","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/SHK.0b013e3181ae8155","volume":"33","author":"NM Nikolaidis","year":"2010","unstructured":"Nikolaidis, N. M. et al. Ron receptor tyrosine kinase negatively regulates tnf\u03b1 production in alveolar macrophages by inhibiting nf-\u03bab activity and adam17 production. Shock 33, 197\u2013204 (2010).","journal-title":"Shock"},{"key":"2840_CR113","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1189\/jlb.0611289","volume":"91","author":"YJ Lee","year":"2012","unstructured":"Lee, Y. J. et al. Inhibiting Mer receptor tyrosine kinase suppresses STAT1, SOCS1\/3, and NF-\u03baB activation and enhances inflammatory responses in lipopolysaccharide-induced acute lung injury. J. Leukoc. Biol. 91, 921\u2013932 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"2840_CR114","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/ni.2064","volume":"12","author":"JM Yuk","year":"2011","unstructured":"Yuk, J. M. et al. The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat. Immunol. 12, 742\u2013751 (2011).","journal-title":"Nat. Immunol."},{"key":"2840_CR115","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/373573a0","volume":"373","author":"T Pawson","year":"1995","unstructured":"Pawson, T. Protein modules and signalling networks. Nature 373, 573\u2013580 (1995).","journal-title":"Nature"},{"key":"2840_CR116","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202154041","volume":"23","author":"K Salokas","year":"2022","unstructured":"Salokas, K. et al. Physical and functional interactome atlas of human receptor tyrosine kinases. EMBO Rep. 23, e54041 (2022).","journal-title":"EMBO Rep."},{"key":"2840_CR117","doi-asserted-by":"publisher","first-page":"T69","DOI":"10.1530\/JME-17-0311","volume":"61","author":"F Hakuno","year":"2018","unstructured":"Hakuno, F. & Takahashi, S. I. 40 years of IGF1: IGF1 receptor signaling pathways. J. Mol. Endocrinol. 61, T69\u2013T86 (2018).","journal-title":"J. Mol. Endocrinol."},{"key":"2840_CR118","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.pa.36.040196.003151","volume":"36","author":"MG Myers Jr","year":"1996","unstructured":"Myers, M. G. Jr & White, M. F. Insulin signal transduction and the IRS proteins. Annu. Rev. Pharmacol. Toxicol. 36, 615\u2013658 (1996).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2840_CR119","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jbior.2014.11.003","volume":"58","author":"RA Bradshaw","year":"2015","unstructured":"Bradshaw, R. A. et al. NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling. Adv. Biol. Regul. 58, 16\u201327 (2015).","journal-title":"Adv. Biol. Regul."},{"key":"2840_CR120","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/j.1349-7006.2008.00840.x","volume":"99","author":"N Gotoh","year":"2008","unstructured":"Gotoh, N. Regulation of growth factor signaling by FRS2 family docking\/scaffold adaptor proteins. Cancer Sci. 99, 1319\u20131325 (2008).","journal-title":"Cancer Sci."},{"key":"2840_CR121","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0092-8674(04)00041-8","volume":"116","author":"Z Songyang","year":"2004","unstructured":"Songyang, Z. & Cantley, L. C. ZIP codes for delivering SH2 domains. Cell 116, S41\u2013S43 (2004). 2 p following S48.","journal-title":"Cell"},{"key":"2840_CR122","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0092-8674(95)90401-8","volume":"80","author":"CJ Marshall","year":"1995","unstructured":"Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179\u2013185 (1995).","journal-title":"Cell"},{"key":"2840_CR123","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/ncb1543","volume":"9","author":"SD Santos","year":"2007","unstructured":"Santos, S. D., Verveer, P. J. & Bastiaens, P. I. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat. Cell Biol. 9, 324\u2013330 (2007).","journal-title":"Nat. Cell Biol."},{"key":"2840_CR124","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrm1838","volume":"7","author":"BN Kholodenko","year":"2006","unstructured":"Kholodenko, B. N. Cell-signalling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 7, 165\u2013176 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2840_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8174","volume":"6","author":"I Yeh","year":"2015","unstructured":"Yeh, I. et al. Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat. Commun. 6, 7174 (2015).","journal-title":"Nat. Commun."},{"key":"2840_CR126","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","volume":"8","author":"P Peschard","year":"2001","unstructured":"Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995\u20131004 (2001).","journal-title":"Mol. Cell"},{"key":"2840_CR127","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1126\/science.1174621","volume":"327","author":"D Lingwood","year":"2010","unstructured":"Lingwood, D. & Simons, K. Lipid rafts as a membrane-organizing principle. Science 327, 46\u201350 (2010).","journal-title":"Science"},{"key":"2840_CR128","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1016\/j.yexcr.2009.07.008","volume":"315","author":"SY Katoh","year":"2009","unstructured":"Katoh, S. Y., Kamimoto, T., Yamakawa, D. & Takakura, N. Lipid rafts serve as signaling platforms for Tie2 receptor tyrosine kinase in vascular endothelial cells. Exp. Cell Res. 315, 2818\u20132823 (2009).","journal-title":"Exp. Cell Res."},{"key":"2840_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004130","volume":"11","author":"J Palacios-Moreno","year":"2015","unstructured":"Palacios-Moreno, J. et al. Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts. PLoS Comput. Biol. 11, e1004130 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"2840_CR130","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1158\/0008-5472.CAN-18-2603","volume":"79","author":"G Zhang","year":"2019","unstructured":"Zhang, G. et al. CD317 activates EGFR by regulating its association with lipid rafts. Cancer Res. 79, 2220\u20132231 (2019).","journal-title":"Cancer Res."},{"key":"2840_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01547-3","volume":"21","author":"Z Pan","year":"2022","unstructured":"Pan, Z. et al. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR\/Src\/Erk\/SP1 signaling-mediated ERR\u03b1 re-expression. Mol. Cancer 21, 77 (2022).","journal-title":"Mol. Cancer"},{"key":"2840_CR132","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.devcel.2008.07.001","volume":"15","author":"M Gonzalez-Gaitan","year":"2008","unstructured":"Gonzalez-Gaitan, M. The garden of forking paths: recycling, signaling, and degradation. Dev. Cell 15, 172\u2013174 (2008).","journal-title":"Dev. Cell"},{"key":"2840_CR133","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1083\/jcb.200806076","volume":"182","author":"S Kermorgant","year":"2008","unstructured":"Kermorgant, S. & Parker, P. J. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J. Cell Biol. 182, 855\u2013863 (2008).","journal-title":"J. Cell Biol."},{"key":"2840_CR134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cytogfr.2024.12.004","volume":"81","author":"YL Chen","year":"2025","unstructured":"Chen, Y. L. et al. Nuclear translocation of RON receptor tyrosine kinase. New mechanistic and functional insights. Cytokine Growth Factor Rev. 81, 9\u201315 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2840_CR135","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1038\/sj.emboj.7600396","volume":"23","author":"S Kermorgant","year":"2004","unstructured":"Kermorgant, S., Zicha, D. & Parker, P. J. PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J. 23, 3721\u20133734 (2004).","journal-title":"EMBO J."},{"key":"2840_CR136","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.devcel.2008.06.012","volume":"15","author":"S Sigismund","year":"2008","unstructured":"Sigismund, S. et al. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 15, 209\u2013219 (2008).","journal-title":"Dev. Cell"},{"key":"2840_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02407-5","volume":"23","author":"K Wu","year":"2025","unstructured":"Wu, K. et al. MSP-RON signaling in liver pathobiology and as an emerging therapeutic target: a review of the current evidence. Cell Commun. Signal. 23, 385 (2025).","journal-title":"Cell Commun. Signal."},{"key":"2840_CR138","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1101\/gad.13.11.1361","volume":"13","author":"M Sahni","year":"1999","unstructured":"Sahni, M. et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13, 1361\u20131366 (1999).","journal-title":"Genes Dev."},{"key":"2840_CR139","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.cell.2017.02.026","volume":"168","author":"AR Kim","year":"2017","unstructured":"Kim, A. R. et al. Functional selectivity in cytokine signaling revealed through a pathogenic EPO mutation. Cell 168, 1053\u20131064.e1015 (2017).","journal-title":"Cell"},{"key":"2840_CR140","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.yexcr.2008.10.033","volume":"315","author":"MJ Lazzara","year":"2009","unstructured":"Lazzara, M. J. & Lauffenburger, D. A. Quantitative modeling perspectives on the ErbB system of cell regulatory processes. Exp. Cell Res. 315, 717\u2013725 (2009).","journal-title":"Exp. Cell Res."},{"key":"2840_CR141","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0962-8924(02)00009-0","volume":"13","author":"HS Wiley","year":"2003","unstructured":"Wiley, H. S., Shvartsman, S. Y. & Lauffenburger, D. A. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol. 13, 43\u201350 (2003).","journal-title":"Trends Cell Biol."},{"key":"2840_CR142","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1124\/mol.107.043794","volume":"73","author":"N Kumar","year":"2008","unstructured":"Kumar, N., Afeyan, R., Kim, H. D. & Lauffenburger, D. A. Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol. Pharmacol. 73, 1668\u20131678 (2008).","journal-title":"Mol. Pharmacol."},{"key":"2840_CR143","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. Nature 521, 436\u2013444 (2015).","journal-title":"Nature"},{"key":"2840_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41146-4","volume":"14","author":"E Hartman","year":"2023","unstructured":"Hartman, E. et al. Interpreting biologically informed neural networks for enhanced proteomic biomarker discovery and pathway analysis. Nat. Commun. 14, 5359 (2023).","journal-title":"Nat. Commun."},{"key":"2840_CR145","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11538-024-01357-2","volume":"86","author":"JT Nardini","year":"2024","unstructured":"Nardini, J. T. Forecasting and predicting stochastic agent-based model data with biologically-informed neural networks. Bull. Math. Biol. 86, 130 (2024).","journal-title":"Bull. Math. Biol."},{"key":"2840_CR146","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41580-025-00892-7","volume":"26","author":"M Abu-Remaileh","year":"2025","unstructured":"Abu-Remaileh, M. et al. Visions of the future of molecular cell biology. Nat. Rev. Mol. Cell Biol. 26, 735\u2013740 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2840_CR147","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1016\/j.cell.2024.11.015","volume":"187","author":"C Bunne","year":"2024","unstructured":"Bunne, C. et al. How to build the virtual cell with artificial intelligence: priorities and opportunities. Cell 187, 7045\u20137063 (2024).","journal-title":"Cell"},{"key":"2840_CR148","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1021\/acs.chemrev.6b00177","volume":"117","author":"NR Latorraca","year":"2017","unstructured":"Latorraca, N. R., Venkatakrishnan, A. J. & Dror, R. O. GPCR dynamics: structures in motion. Chem. Rev. 117, 139\u2013155 (2017).","journal-title":"Chem. Rev."},{"key":"2840_CR149","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"AS Hauser","year":"2017","unstructured":"Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schi\u00f6th, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829\u2013842 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2840_CR150","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1124\/pr.119.018044","volume":"71","author":"HA Dunn","year":"2019","unstructured":"Dunn, H. A., Orlandi, C. & Martemyanov, K. A. Beyond the ligand: extracellular and transcellular G protein-coupled receptor complexes in physiology and pharmacology. Pharmacol. Rev. 71, 503\u2013519 (2019).","journal-title":"Pharmacol. Rev."},{"key":"2840_CR151","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/47260","volume":"402","author":"N Prenzel","year":"1999","unstructured":"Prenzel, N. et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884\u2013888 (1999).","journal-title":"Nature"},{"key":"2840_CR152","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1074\/jbc.M008570200","volume":"276","author":"S Eguchi","year":"2001","unstructured":"Eguchi, S., Dempsey, P. J., Frank, G. D., Motley, E. D. & Inagami, T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J. Biol. Chem. 276, 7957\u20137962 (2001).","journal-title":"J. Biol. Chem."},{"key":"2840_CR153","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1161\/01.RES.87.2.92","volume":"87","author":"A Kalmes","year":"2000","unstructured":"Kalmes, A., Vesti, B. R., Daum, G., Abraham, J. A. & Clowes, A. W. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ. Res. 87, 92\u201398 (2000).","journal-title":"Circ. Res."},{"key":"2840_CR154","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1161\/01.RES.0000109413.57726.91","volume":"94","author":"L Hao","year":"2004","unstructured":"Hao, L., Du, M., Lopez-Campistrous, A. & Fernandez-Patron, C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res. 94, 68\u201376 (2004).","journal-title":"Circ. Res."},{"key":"2840_CR155","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1210\/me.2010-0410","volume":"25","author":"L Carbajal","year":"2011","unstructured":"Carbajal, L., Biswas, A., Niswander, L. M., Prizant, H. & Hammes, S. R. GPCR\/EGFR cross-talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. Mol. Endocrinol. 25, 1055\u20131065 (2011).","journal-title":"Mol. Endocrinol."},{"key":"2840_CR156","doi-asserted-by":"publisher","first-page":"8335","DOI":"10.1074\/jbc.274.12.8335","volume":"274","author":"JS Biscardi","year":"1999","unstructured":"Biscardi, J. S. et al. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 274, 8335\u20138343 (1999).","journal-title":"J. Biol. Chem."},{"key":"2840_CR157","doi-asserted-by":"publisher","first-page":"12619","DOI":"10.1074\/jbc.275.17.12619","volume":"275","author":"SJ Keely","year":"2000","unstructured":"Keely, S. J., Calandrella, S. O. & Barrett, K. E. Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular Ca2+, PYK-2, and p60(src). J. Biol. Chem. 275, 12619\u201312625 (2000).","journal-title":"J. Biol. Chem."},{"key":"2840_CR158","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bone.2013.12.014","volume":"60","author":"CL Tsai","year":"2014","unstructured":"Tsai, C. L. et al. c-Src-dependent transactivation of PDGFR contributes to TNF-\u03b1-induced MMP-9 expression and functional impairment in osteoblasts. Bone 60, 186\u2013197 (2014).","journal-title":"Bone"},{"key":"2840_CR159","doi-asserted-by":"publisher","first-page":"28970","DOI":"10.1074\/jbc.M402508200","volume":"279","author":"OM Fischer","year":"2004","unstructured":"Fischer, O. M., Giordano, S., Comoglio, P. M. & Ullrich, A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem. 279, 28970\u201328978 (2004).","journal-title":"J. Biol. Chem."},{"key":"2840_CR160","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.freeradbiomed.2011.05.040","volume":"51","author":"F Cattaneo","year":"2011","unstructured":"Cattaneo, F., Iaccio, A., Guerra, G., Montagnani, S. & Ammendola, R. NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells. Free Radic. Biol. Med. 51, 1126\u20131136 (2011).","journal-title":"Free Radic. Biol. Med."},{"key":"2840_CR161","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cellsig.2010.05.012","volume":"22","author":"N El Zein","year":"2010","unstructured":"El Zein, N., D\u2019Hondt, S. & Sariban, E. Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation. Cell. Signal. 22, 1437\u20131447 (2010).","journal-title":"Cell. Signal."},{"key":"2840_CR162","first-page":"1","volume":"339","author":"C Crudden","year":"2018","unstructured":"Crudden, C. et al. Blurring boundaries: receptor tyrosine kinases as functional G protein-coupled receptors. Int. Rev. Cell Mol. Biol. 339, 1\u201340 (2018).","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"2840_CR163","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1074\/jbc.275.4.2255","volume":"275","author":"H Hallak","year":"2000","unstructured":"Hallak, H., Seiler, A. E., Green, J. S., Ross, B. N. & Rubin, R. Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation. J. Biol. Chem. 275, 2255\u20132258 (2000).","journal-title":"J. Biol. Chem."},{"key":"2840_CR164","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1042\/bj2350145","volume":"235","author":"CM Heyworth","year":"1986","unstructured":"Heyworth, C. M., Grey, A. M., Wilson, S. R., Hanski, E. & Houslay, M. D. The action of islet activating protein (pertussis toxin) on insulin\u2019s ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes. Biochem. J. 235, 145\u2013149 (1986).","journal-title":"Biochem. J."},{"key":"2840_CR165","doi-asserted-by":"publisher","first-page":"20375","DOI":"10.1074\/jbc.M109.005793","volume":"284","author":"DG Tilley","year":"2009","unstructured":"Tilley, D. G., Kim, I. M., Patel, P. A., Violin, J. D. & Rockman, H. A. beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J. Biol. Chem. 284, 20375\u201320386 (2009).","journal-title":"J. Biol. Chem."},{"key":"2840_CR166","doi-asserted-by":"publisher","first-page":"28578","DOI":"10.1074\/jbc.M102771200","volume":"276","author":"F Alderton","year":"2001","unstructured":"Alderton, F. et al. Tethering of the platelet-derived growth factor beta receptor to G-protein-coupled receptors. A novel platform for integrative signaling by these receptor classes in mammalian cells. J. Biol. Chem. 276, 28578\u201328585 (2001).","journal-title":"J. Biol. Chem."},{"key":"2840_CR167","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0026-895X(24)23050-9","volume":"60","author":"S Rakhit","year":"2001","unstructured":"Rakhit, S., Pyne, S. & Pyne, N. J. Nerve growth factor stimulation of p42\/p44 mitogen-activated protein kinase in PC12 cells: role of G(i\/o), G protein-coupled receptor kinase 2, beta-arrestin I, and endocytic processing. Mol. Pharmacol. 60, 63\u201370 (2001).","journal-title":"Mol. Pharmacol."},{"key":"2840_CR168","doi-asserted-by":"publisher","first-page":"6272","DOI":"10.1128\/MCB.22.17.6272-6285.2002","volume":"22","author":"S Dalle","year":"2002","unstructured":"Dalle, S. et al. Insulin induces heterologous desensitization of G-protein-coupled receptor and insulin-like growth factor I signaling by downregulating beta-arrestin-1. Mol. Cell. Biol. 22, 6272\u20136285 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"2840_CR169","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1210\/endrev\/bnaf019","volume":"46","author":"L Girnita","year":"2025","unstructured":"Girnita, L., Janssen, J. & Smith, T. J. G-protein coupled & membrane tyrosine kinase receptors relationship yield therapy opportunities. Endocr. Rev. 46, 810\u2013837 (2025).","journal-title":"Endocr. Rev."},{"key":"2840_CR170","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuropharm.2018.11.018","volume":"152","author":"V Di Liberto","year":"2019","unstructured":"Di Liberto, V., Mud\u00f2, G. & Belluardo, N. Crosstalk between receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCR) in the brain: Focus on heteroreceptor complexes and related functional neurotrophic effects. Neuropharmacology 152, 67\u201377 (2019).","journal-title":"Neuropharmacology"},{"key":"2840_CR171","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cbin.11797","volume":"46","author":"R Hayat","year":"2022","unstructured":"Hayat, R., Manzoor, M. & Hussain, A. Wnt signaling pathway: a comprehensive review. Cell Biol. Int. 46, 863\u2013877 (2022).","journal-title":"Cell Biol. Int."},{"key":"2840_CR172","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nature04185","volume":"438","author":"X Zeng","year":"2005","unstructured":"Zeng, X. et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438, 873\u2013877 (2005).","journal-title":"Nature"},{"key":"2840_CR173","first-page":"2967","volume":"127","author":"NT Georgopoulos","year":"2014","unstructured":"Georgopoulos, N. T., Kirkwood, L. A. & Southgate, J. A novel bidirectional positive-feedback loop between Wnt-\u03b2-catenin and EGFR-ERK plays a role in context-specific modulation of epithelial tissue regeneration. J. Cell Sci. 127, 2967\u20132982 (2014).","journal-title":"J. Cell Sci."},{"key":"2840_CR174","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcmgh.2020.04.007","volume":"10","author":"A Prossomariti","year":"2020","unstructured":"Prossomariti, A., Piazzi, G., Alquati, C. & Ricciardiello, L. Are Wnt\/\u03b2-catenin and PI3K\/AKT\/mTORC1 distinct pathways in colorectal cancer? Cell. Mol. Gastroenterol. Hepatol. 10, 491\u2013506 (2020).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"2840_CR175","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1423-0127-19-67","volume":"19","author":"IA Voutsadakis","year":"2012","unstructured":"Voutsadakis, I. A. The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial-Mesenchymal transition of cancer. J. Biomed. Sci. 19, 67 (2012).","journal-title":"J. Biomed. Sci."},{"key":"2840_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-236","volume":"9","author":"T Hu","year":"2010","unstructured":"Hu, T. & Li, C. Convergence between Wnt-\u03b2-catenin and EGFR signaling in cancer. Mol. Cancer 9, 236 (2010).","journal-title":"Mol. Cancer"},{"key":"2840_CR177","doi-asserted-by":"publisher","first-page":"a009175","DOI":"10.1101\/cshperspect.a009175","volume":"6","author":"J Green","year":"2014","unstructured":"Green, J., Nusse, R. & van Amerongen, R. The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction. Cold Spring Harb. Perspect. Biol. 6, a009175 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2840_CR178","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/abbs\/gmr079","volume":"43","author":"A De","year":"2011","unstructured":"De, A. Wnt\/Ca2+ signaling pathway: a brief overview. Acta Biochim. Biophys. Sin. 43, 745\u2013756 (2011).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"2840_CR179","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cellsig.2006.11.001","volume":"19","author":"A Kikuchi","year":"2007","unstructured":"Kikuchi, A., Yamamoto, H. & Kishida, S. Multiplicity of the interactions of Wnt proteins and their receptors. Cell. Signal. 19, 659\u2013671 (2007).","journal-title":"Cell. Signal."},{"key":"2840_CR180","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1083\/jcb.200607127","volume":"175","author":"M Nishita","year":"2006","unstructured":"Nishita, M. et al. Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration. J. Cell Biol. 175, 555\u2013562 (2006).","journal-title":"J. Cell Biol."},{"key":"2840_CR181","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2012.11.003","volume":"151","author":"X Guo","year":"2012","unstructured":"Guo, X. & Wang, X. F. A mediator lost in the war on cancer. Cell 151, 927\u2013929 (2012).","journal-title":"Cell"},{"key":"2840_CR182","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2008.07.025","volume":"134","author":"MO Li","year":"2008","unstructured":"Li, M. O. & Flavell, R. A. TGF-beta: a master of all T cell trades. Cell 134, 392\u2013404 (2008).","journal-title":"Cell"},{"key":"2840_CR183","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1172\/JCI24652","volume":"116","author":"M Jechlinger","year":"2006","unstructured":"Jechlinger, M. et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Investig. 116, 1561\u20131570 (2006).","journal-title":"J. Clin. Investig."},{"key":"2840_CR184","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/cr.2008.328","volume":"19","author":"YE Zhang","year":"2009","unstructured":"Zhang, Y. E. Non-Smad pathways in TGF-beta signaling. Cell Res. 19, 128\u2013139 (2009).","journal-title":"Cell Res."},{"key":"2840_CR185","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.neo.2015.06.004","volume":"17","author":"E Jo","year":"2015","unstructured":"Jo, E., Park, S. J., Choi, Y. S., Jeon, W. K. & Kim, B. C. Kaempferol suppresses transforming growth factor-\u03b21-induced epithelial-to-mesenchymal transition and migration of A549 lung cancer cells by inhibiting Akt1-mediated phosphorylation of Smad3 at threonine-179. Neoplasia 17, 525\u2013537 (2015).","journal-title":"Neoplasia"},{"key":"2840_CR186","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ncb1113","volume":"6","author":"I Remy","year":"2004","unstructured":"Remy, I., Montmarquette, A. & Michnick, S. W. PKB\/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat. Cell Biol. 6, 358\u2013365 (2004).","journal-title":"Nat. Cell Biol."},{"key":"2840_CR187","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1681\/ASN.2011070645","volume":"23","author":"J Chen","year":"2012","unstructured":"Chen, J. et al. EGFR signaling promotes TGF\u03b2-dependent renal fibrosis. J. Am. Soc. Nephrol. 23, 215\u2013224 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2840_CR188","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1038\/onc.2010.112","volume":"29","author":"SE Wang","year":"2010","unstructured":"Wang, S. E. et al. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene 29, 3335\u20133348 (2010).","journal-title":"Oncogene"},{"key":"2840_CR189","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.1073\/pnas.1510837112","volume":"112","author":"Z Wang","year":"2015","unstructured":"Wang, Z. et al. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Proc. Natl. Acad. Sci. USA 112, 9990\u20139995 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2840_CR190","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/liv.14892","volume":"41","author":"T Weng","year":"2021","unstructured":"Weng, T. et al. The MSP-RON pathway regulates liver fibrosis through transforming growth factor beta-dependent epithelial\u2013mesenchymal transition. Liver Int. 41, 1956\u20131968 (2021).","journal-title":"Liver Int."},{"key":"2840_CR191","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s11427-017-9173-5","volume":"60","author":"Q Shi","year":"2017","unstructured":"Shi, Q. & Chen, Y. G. Interplay between TGF-\u03b2 signaling and receptor tyrosine kinases in tumor development. Sci China Life Sci 60, 1133\u20131141 (2017).","journal-title":"Sci China Life Sci"},{"key":"2840_CR192","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275\u2013291 (2014).","journal-title":"Cell Stem Cell"},{"key":"2840_CR193","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.stem.2018.12.009","volume":"24","author":"BC Prager","year":"2019","unstructured":"Prager, B. C., Xie, Q., Bao, S. & Rich, J. N. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24, 41\u201353 (2019).","journal-title":"Cell Stem Cell"},{"key":"2840_CR194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2014.05.001","volume":"26","author":"J Chen","year":"2015","unstructured":"Chen, J., Song, W. & Amato, K. Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev. 26, 1\u20136 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2840_CR195","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1158\/0008-5472.CAN-20-2773","volume":"81","author":"M Gao","year":"2021","unstructured":"Gao, M. et al. EGFR activates a TAZ-driven oncogenic program in glioblastoma. Cancer Res. 81, 3580\u20133592 (2021).","journal-title":"Cancer Res."},{"key":"2840_CR196","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz0868","volume":"370","author":"HT Nia","year":"2020","unstructured":"Nia, H. T., Munn, L. L. & Jain, R. K. Physical traits of cancer. Science 370, eaaz0868 (2020).","journal-title":"Science"},{"key":"2840_CR197","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","volume":"599","author":"X Sun","year":"2021","unstructured":"Sun, X. et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature 599, 673\u2013678 (2021).","journal-title":"Nature"},{"key":"2840_CR198","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s41418-023-01166-5","volume":"30","author":"YX Xiong","year":"2023","unstructured":"Xiong, Y. X. et al. Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression. Cell Death Differ. 30, 1648\u20131665 (2023).","journal-title":"Cell Death Differ."},{"key":"2840_CR199","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","volume":"39","author":"X Guan","year":"2019","unstructured":"Guan, X. et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun. 39, 1 (2019).","journal-title":"Cancer Commun."},{"key":"2840_CR200","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","volume":"616","author":"M Debaugnies","year":"2023","unstructured":"Debaugnies, M. et al. RHOJ controls EMT-associated resistance to chemotherapy. Nature 616, 168\u2013175 (2023).","journal-title":"Nature"},{"key":"2840_CR201","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1038\/sj.onc.1208664","volume":"24","author":"MM Murillo","year":"2005","unstructured":"Murillo, M. M., del Castillo, G., S\u00e1nchez, A., Fern\u00e1ndez, M. & Fabregat, I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 24, 4580\u20134587 (2005).","journal-title":"Oncogene"},{"key":"2840_CR202","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12951-024-03077-0","volume":"22","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. PDGFR-\u03b1 shRNA-polyplex for uveal melanoma treatment via EMT-mediated vasculogenic mimicry interfering. J. Nanobiotechnol. 22, 797 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2840_CR203","doi-asserted-by":"publisher","first-page":"117897","DOI":"10.1016\/j.ejmech.2025.117897","volume":"296","author":"X Liu","year":"2025","unstructured":"Liu, X., Mei, W., Yao, Y. & Zeng, C. Current insights and barriers in FGFR-mediated signaling in lung cancer. Eur. J. Med. Chem. 296, 117897 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"2840_CR204","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-17-0392","volume":"77","author":"J Antony","year":"2017","unstructured":"Antony, J. & Huang, R. Y. AXL-driven EMT state as a targetable conduit in cancer. Cancer Res. 77, 3725\u20133732 (2017).","journal-title":"Cancer Res."},{"key":"2840_CR205","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279\u2013290 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2840_CR206","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457\u2013474 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR207","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873\u2013887 (2011).","journal-title":"Cell"},{"key":"2840_CR208","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","volume":"10","author":"C Lee","year":"2025","unstructured":"Lee, C. et al. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct. Target Ther. 10, 170 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2840_CR209","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","volume":"24","author":"S Guelfi","year":"2024","unstructured":"Guelfi, S., Hodivala-Dilke, K. & Bergers, G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat. Rev. Cancer 24, 655\u2013675 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR210","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P. & Griffioen, A. W. Anti-angiogenic agents\u2014overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol. 18, 527\u2013540 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2840_CR211","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","volume":"69","author":"J Ozao-Choy","year":"2009","unstructured":"Ozao-Choy, J. et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69, 2514\u20132522 (2009).","journal-title":"Cancer Res."},{"key":"2840_CR212","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30, R921\u2013R925 (2020).","journal-title":"Curr. Biol."},{"key":"2840_CR213","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","volume":"42","author":"Y Tang","year":"2023","unstructured":"Tang, Y., Zang, H., Wen, Q. & Fan, S. AXL in cancer: a modulator of drug resistance and therapeutic target. J. Exp. Clin. Cancer Res. 42, 148 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2840_CR214","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/gutjnl-2022-329134","volume":"72","author":"LL Cao","year":"2023","unstructured":"Cao, L. L. et al. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-\u03b3 signalling. Gut 72, 2038\u20132050 (2023).","journal-title":"Gut"},{"key":"2840_CR215","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911814","volume":"14","author":"I Berestjuk","year":"2022","unstructured":"Berestjuk, I. et al. Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma. EMBO Mol. Med. 14, e11814 (2022).","journal-title":"EMBO Mol. Med."},{"key":"2840_CR216","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2018.12.004","volume":"70","author":"M Cadamuro","year":"2019","unstructured":"Cadamuro, M. et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J. Hepatol. 70, 700\u2013709 (2019).","journal-title":"J. Hepatol."},{"key":"2840_CR217","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669\u2013680 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR218","doi-asserted-by":"publisher","first-page":"217076","DOI":"10.1016\/j.canlet.2024.217076","volume":"597","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications. Cancer Lett. 597, 217076 (2024).","journal-title":"Cancer Lett."},{"key":"2840_CR219","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10427-2","volume":"10","author":"N Jin","year":"2019","unstructured":"Jin, N. et al. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Nat. Commun. 10, 2701 (2019).","journal-title":"Nat. Commun."},{"key":"2840_CR220","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49673-4","volume":"15","author":"C Zhong","year":"2024","unstructured":"Zhong, C. et al. CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer. Nat. Commun. 15, 5502 (2024).","journal-title":"Nat. Commun."},{"key":"2840_CR221","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/s41388-020-01577-5","volume":"40","author":"GE Wood","year":"2021","unstructured":"Wood, G. E., Hockings, H., Hilton, D. M. & Kermorgant, S. The role of MET in chemotherapy resistance. Oncogene 40, 1927\u20131941 (2021).","journal-title":"Oncogene"},{"key":"2840_CR222","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13046-023-02623-2","volume":"42","author":"K Fang","year":"2023","unstructured":"Fang, K. et al. Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia. J. Exp. Clin. Cancer Res. 42, 73 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2840_CR223","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2008.04.017","volume":"268","author":"CC Hong","year":"2008","unstructured":"Hong, C. C. et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268, 314\u2013324 (2008).","journal-title":"Cancer Lett."},{"key":"2840_CR224","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1158\/1535-7163.MCT-17-0587","volume":"16","author":"ML Palisoul","year":"2017","unstructured":"Palisoul, M. L. et al. Inhibition of the receptor tyrosine kinase AXL restores paclitaxel chemosensitivity in uterine serous cancer. Mol. Cancer Ther. 16, 2881\u20132891 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"2840_CR225","doi-asserted-by":"publisher","first-page":"10663","DOI":"10.1021\/acs.jmedchem.5c00239","volume":"68","author":"DH Miles","year":"2025","unstructured":"Miles, D. H. et al. Discovery of AB801, a potent and selective inhibitor of AXL receptor tyrosine kinase for use in cancer therapy. J. Med. Chem. 68, 10663\u201310676 (2025).","journal-title":"J. Med. Chem."},{"key":"2840_CR226","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P Libby","year":"2002","unstructured":"Libby, P. Inflammation in atherosclerosis. Nature 420, 868\u2013874 (2002).","journal-title":"Nature"},{"key":"2840_CR227","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12951-025-03384-0","volume":"23","author":"L Tu","year":"2025","unstructured":"Tu, L. et al. Targeted drug delivery systems for atherosclerosis. J. Nanobiotechnol. 23, 306 (2025).","journal-title":"J. Nanobiotechnol."},{"key":"2840_CR228","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jacc.2017.10.084","volume":"71","author":"L Zeboudj","year":"2018","unstructured":"Zeboudj, L. et al. Selective EGF-receptor inhibition in CD4(+) T cells induces anergy and limits atherosclerosis. J. Am. Coll. Cardiol. 71, 160\u2013172 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2840_CR229","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.immunol.17.1.19","volume":"17","author":"TA Waldmann","year":"1999","unstructured":"Waldmann, T. A. & Tagaya, Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17, 19\u201349 (1999).","journal-title":"Annu. Rev. Immunol."},{"key":"2840_CR230","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.116.026644","volume":"136","author":"AC Finney","year":"2017","unstructured":"Finney, A. C. et al. EphA2 expression regulates inflammation and fibroproliferative remodeling in atherosclerosis. Circulation 136, 566\u2013582 (2017).","journal-title":"Circulation"},{"key":"2840_CR231","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.phrs.2012.10.008","volume":"67","author":"SD Funk","year":"2013","unstructured":"Funk, S. D. & Orr, A. W. Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis. Pharmacol. Res. 67, 42\u201352 (2013).","journal-title":"Pharmacol. Res."},{"key":"2840_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-024-00585-7","volume":"10","author":"C Lu","year":"2024","unstructured":"Lu, C. et al. EphA2 blockage ALW-II-41-27 alleviates atherosclerosis by remodeling gut microbiota to regulate bile acid metabolism. NPJ Biofilms Microbiomes 10, 108 (2024).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2840_CR233","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.115.015308","volume":"131","author":"Z Lin","year":"2015","unstructured":"Lin, Z. et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131, 1861\u20131871 (2015).","journal-title":"Circulation"},{"key":"2840_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2019.158547","volume":"1865","author":"CJ Zhang","year":"2020","unstructured":"Zhang, C. J. et al. Wnt5a\/Ror2 pathway contributes to the regulation of cholesterol homeostasis and inflammatory response in atherosclerosis. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1865, 158547 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"2840_CR235","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s44161-023-00224-y","volume":"2","author":"A Anisimov","year":"2023","unstructured":"Anisimov, A. et al. The angiopoietin receptor Tie2 is atheroprotective in arterial endothelium. Nat. Cardiovasc. Res. 2, 307\u2013321 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"2840_CR236","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1172\/JCI42040","volume":"121","author":"KV Woo","year":"2011","unstructured":"Woo, K. V. et al. Tie1 attenuation reduces murine atherosclerosis in a dose-dependent and shear stress-specific manner. J. Clin. Investig. 121, 1624\u20131635 (2011).","journal-title":"J. Clin. Investig."},{"key":"2840_CR237","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/biom14111446","volume":"14","author":"CN Ma","year":"2024","unstructured":"Ma, C. N. et al. Targeting PDGF\/PDGFR signaling pathway by microRNA, lncRNA, and circRNA for therapy of vascular diseases: a narrow review. Biomolecules 14, 1446 (2024).","journal-title":"Biomolecules"},{"key":"2840_CR238","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cytogfr.2004.03.004","volume":"15","author":"EW Raines","year":"2004","unstructured":"Raines, E. W. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 15, 237\u2013254 (2004).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2840_CR239","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5551\/jat.13.130","volume":"13","author":"T Matsumoto","year":"2006","unstructured":"Matsumoto, T. & Mugishima, H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J. Atheroscler. Thromb. 13, 130\u2013135 (2006).","journal-title":"J. Atheroscler. Thromb."},{"key":"2840_CR240","doi-asserted-by":"publisher","first-page":"2401830","DOI":"10.1183\/13993003.01830-2024","volume":"66","author":"O Sitbon","year":"2025","unstructured":"Sitbon, O. et al. Drugs targeting novel pathways in pulmonary arterial hypertension. Eur. Respir. J. 66, 2401830 (2025).","journal-title":"Eur. Respir. J."},{"key":"2840_CR241","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun, P. M. Pulmonary Arterial Hypertension. N. Engl. J. Med. 385, 2361\u20132376 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR242","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.042713","volume":"14","author":"W Wu","year":"2025","unstructured":"Wu, W. et al. Novel insights into receptor tyrosine kinases in pulmonary arterial hypertension. J. Am. Heart Assoc. 14, e042713 (2025).","journal-title":"J. Am. Heart Assoc."},{"key":"2840_CR243","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40256-023-00596-3","volume":"23","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. Receptor tyrosine kinase: still an interesting target to inhibit the proliferation of vascular smooth muscle cells. Am. J. Cardiovasc. Drugs 23, 497\u2013518 (2023).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"2840_CR244","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1161\/ATVBAHA.123.319839","volume":"43","author":"Y Zhong","year":"2023","unstructured":"Zhong, Y. & Yu, P. B. Angiogenesis redux: an overall protective role of VEGF\/KDR signaling in the microvasculature in pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 43, 1784\u20131787 (2023).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2840_CR245","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00395-020-0811-5","volume":"115","author":"MP Winter","year":"2020","unstructured":"Winter, M. P. et al. Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension. Basic Res. Cardiol. 115, 58 (2020).","journal-title":"Basic Res. Cardiol."},{"key":"2840_CR246","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/path.953","volume":"195","author":"RM Tuder","year":"2001","unstructured":"Tuder, R. M. et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J. Pathol. 195, 367\u2013374 (2001).","journal-title":"J. Pathol."},{"key":"2840_CR247","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1161\/CIRCULATIONAHA.122.061900","volume":"146","author":"W Zhou","year":"2022","unstructured":"Zhou, W. et al. Targeting VEGF-A\/VEGFR2 Y949 signaling-mediated vascular permeability alleviates hypoxic pulmonary hypertension. Circulation 146, 1855\u20131881 (2022).","journal-title":"Circulation"},{"key":"2840_CR248","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/HJH.0000000000003220","volume":"40","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Methylation-mediated silencing of PTPRD induces pulmonary hypertension by promoting pulmonary arterial smooth muscle cell migration via the PDGFRB\/PLC\u03b31 axis. J. Hypertens. 40, 1795\u20131807 (2022).","journal-title":"J. Hypertens."},{"key":"2840_CR249","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41569-024-01064-4","volume":"22","author":"HA Ghofrani","year":"2025","unstructured":"Ghofrani, H. A., Gomberg-Maitland, M., Zhao, L. & Grimminger, F. Mechanisms and treatment of pulmonary arterial hypertension. Nat. Rev. Cardiol. 22, 105\u2013120 (2025).","journal-title":"Nat. Rev. Cardiol."},{"key":"2840_CR250","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","volume":"182","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani, H. A. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182, 1171\u20131177 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2840_CR251","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S2213-2600(24)00072-9","volume":"12","author":"RP Frantz","year":"2024","unstructured":"Frantz, R. P. et al. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir. Med. 12, 523\u2013534 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2840_CR252","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.123.067005","volume":"150","author":"JS Bian","year":"2024","unstructured":"Bian, J. S. et al. ErbB3 governs endothelial dysfunction in hypoxia-induced pulmonary hypertension. Circulation 150, 1533\u20131553 (2024).","journal-title":"Circulation"},{"key":"2840_CR253","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1164\/rccm.200811-1682OC","volume":"181","author":"BK Dahal","year":"2010","unstructured":"Dahal, B. K. et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. 181, 158\u2013167 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2840_CR254","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1161\/CIRCULATIONAHA.105.540542","volume":"112","author":"SL Merklinger","year":"2005","unstructured":"Merklinger, S. L., Jones, P. L., Martinez, E. C. & Rabinovitch, M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112, 423\u2013431 (2005).","journal-title":"Circulation"},{"key":"2840_CR255","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00037-2019","volume":"5","author":"J Saleby","year":"2019","unstructured":"Saleby, J., Bouzina, H., Ahmed, S., Lundgren, J. & Radegran, G. Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ Open Res. 5, 00037-2019 (2019).","journal-title":"ERJ Open Res."},{"key":"2840_CR256","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40291-016-0214-3","volume":"20","author":"M Liang","year":"2016","unstructured":"Liang, M., Pang, Y., Zhang, S. & Zhang, M. Utility of hepatocyte growth factor as a biomarker for early diagnosis of pulmonary artery hypertension. Mol. Diagn. Ther. 20, 463\u2013468 (2016).","journal-title":"Mol. Diagn. Ther."},{"key":"2840_CR257","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/eurheartj\/ehq226","volume":"31","author":"P K\u00fcmpers","year":"2010","unstructured":"K\u00fcmpers, P. et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur. Heart J. 31, 2291\u20132300 (2010).","journal-title":"Eur. Heart J."},{"key":"2840_CR258","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s12272-024-01503-3","volume":"47","author":"X Fei","year":"2024","unstructured":"Fei, X. et al. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration. Arch. Pharm. Res. 47, 538\u2013557 (2024).","journal-title":"Arch. Pharm. Res."},{"key":"2840_CR259","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ophtha.2016.10.010","volume":"124","author":"GJ Jaffe","year":"2017","unstructured":"Jaffe, G. J. et al. Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter, randomized controlled trial. Ophthalmology 124, 224\u2013234 (2017).","journal-title":"Ophthalmology"},{"key":"2840_CR260","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.oret.2025.05.004","volume":"9","author":"NJS London","year":"2025","unstructured":"London, N. J. S. et al. Outcomes by faricimab treatment interval at week 48 of TENAYA-LUCERNE phase III trials in neovascular age-related macular degeneration. Ophthalmol. Retina 9, 1081\u20131089 (2025).","journal-title":"Ophthalmol. Retina"},{"key":"2840_CR261","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/bjo-2024-326006","volume":"109","author":"W Zhang","year":"2025","unstructured":"Zhang, W. et al. Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial. Br. J. Ophthalmol. 109, 784\u2013790 (2025).","journal-title":"Br. J. Ophthalmol."},{"key":"2840_CR262","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.7150\/thno.72947","volume":"12","author":"A Alli-Shaik","year":"2022","unstructured":"Alli-Shaik, A. et al. System-wide vitreous proteome dissection reveals impaired sheddase activity in diabetic retinopathy. Theranostics 12, 6682\u20136704 (2022).","journal-title":"Theranostics"},{"key":"2840_CR263","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/539179a","volume":"539","author":"MT Heemels","year":"2016","unstructured":"Heemels, M. T. Neurodegenerative diseases. Nature 539, 179 (2016).","journal-title":"Nature"},{"key":"2840_CR264","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/jnr.24542","volume":"98","author":"X Ma","year":"2020","unstructured":"Ma, X. & Qiu, S. Control of cortical synapse development and plasticity by MET receptor tyrosine kinase, a genetic risk factor for autism. J. Neurosci. Res. 98, 2115\u20132129 (2020).","journal-title":"J. Neurosci. Res."},{"key":"2840_CR265","doi-asserted-by":"publisher","first-page":"e56937","DOI":"10.15252\/embr.202356937","volume":"24","author":"T Christova","year":"2023","unstructured":"Christova, T., Ho, S. K., Liu, Y., Gill, M. & Attisano, L. LTK and ALK promote neuronal polarity and cortical migration by inhibiting IGF1R activity. EMBO Rep. 24, e56937 (2023).","journal-title":"EMBO Rep."},{"key":"2840_CR266","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Primers 7, 33 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2840_CR267","doi-asserted-by":"publisher","first-page":"a004457","DOI":"10.1101\/cshperspect.a004457","volume":"3","author":"DJ Selkoe","year":"2011","unstructured":"Selkoe, D. J. Alzheimer\u2019s disease. Cold Spring Harb. Perspect. Biol. 3, a004457 (2011).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2840_CR268","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrn.2017.48","volume":"18","author":"K Kisler","year":"2017","unstructured":"Kisler, K., Nelson, A. R., Montagne, A. & Zlokovic, B. V. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 18, 419\u2013434 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"2840_CR269","doi-asserted-by":"publisher","first-page":"102349","DOI":"10.1016\/j.arr.2024.102349","volume":"99","author":"N Bregman-Yemini","year":"2024","unstructured":"Bregman-Yemini, N., Nitzan, K., Franko, M. & Doron, R. Connecting the emotional-cognitive puzzle: the role of tyrosine kinase B (TrkB) receptor isoform imbalance in age-related emotional and cognitive impairments. Ageing Res. Rev. 99, 102349 (2024).","journal-title":"Ageing Res. Rev."},{"key":"2840_CR270","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1172\/JCI41356","volume":"120","author":"SM Massa","year":"2010","unstructured":"Massa, S. M. et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Investig. 120, 1774\u20131785 (2010).","journal-title":"J. Clin. Investig."},{"key":"2840_CR271","doi-asserted-by":"publisher","first-page":"113595","DOI":"10.1016\/j.celrep.2023.113595","volume":"43","author":"C Lao-Peregrin","year":"2024","unstructured":"Lao-Peregrin, C. et al. Synaptic plasticity via receptor tyrosine kinase\/G-protein-coupled receptor crosstalk. Cell Rep. 43, 113595 (2024).","journal-title":"Cell Rep."},{"key":"2840_CR272","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/d41586-020-01152-8","volume":"581","author":"M Ishii","year":"2020","unstructured":"Ishii, M. & Iadecola, C. Risk factor for Alzheimer\u2019s disease breaks the blood-brain barrier. Nature 581, 31\u201332 (2020).","journal-title":"Nature"},{"key":"2840_CR273","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/ph15040471","volume":"15","author":"X Fu","year":"2022","unstructured":"Fu, X., Wang, J., Cai, H., Jiang, H. & Han, S. C16 peptide and Ang-1 improve functional disability and pathological changes in an Alzheimer\u2019s disease model associated with vascular dysfunction. Pharmaceuticals 15, 471 (2022).","journal-title":"Pharmaceuticals"},{"key":"2840_CR274","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.4103\/NRR.NRR-D-23-02004","volume":"20","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Novel genes involved in vascular dysfunction of the middle temporal gyrus in Alzheimer\u2019s disease: transcriptomics combined with machine learning analysis. Neural Regen. Res. 20, 3620\u20133634 (2025).","journal-title":"Neural Regen. Res."},{"key":"2840_CR275","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature09635","volume":"469","author":"M Ciss\u00e9","year":"2011","unstructured":"Ciss\u00e9, M. et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47\u201352 (2011).","journal-title":"Nature"},{"key":"2840_CR276","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.1073\/pnas.1405803111","volume":"111","author":"AK Fu","year":"2014","unstructured":"Fu, A. K. et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer\u2019s disease. Proc. Natl. Acad. Sci. USA 111, 9959\u20139964 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2840_CR277","doi-asserted-by":"publisher","first-page":"108099","DOI":"10.1016\/j.jbc.2024.108099","volume":"301","author":"M Matsumoto","year":"2025","unstructured":"Matsumoto, M., Gomez-Soler, M., Lombardi, S., Lechtenberg, B. C. & Pasquale, E. B. Missense mutations of the ephrin receptor EPHA1 associated with Alzheimer\u2019s disease disrupt receptor signaling functions. J. Biol. Chem. 301, 108099 (2025).","journal-title":"J. Biol. Chem."},{"key":"2840_CR278","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41531-025-01055-3","volume":"11","author":"L Phan","year":"2025","unstructured":"Phan, L. et al. Parkinson\u2019s paradox: alpha-synuclein\u2019s selective strike on SNc dopamine neurons over VTA. NPJ Parkinsons Dis. 11, 207 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"2840_CR279","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang, A. E. & Espay, A. J. Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov. Disord. 33, 660\u2013677 (2018).","journal-title":"Mov. Disord."},{"key":"2840_CR280","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/350230a0","volume":"350","author":"C Hyman","year":"1991","unstructured":"Hyman, C. et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230\u2013232 (1991).","journal-title":"Nature"},{"key":"2840_CR281","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/exnr.2000.7483","volume":"166","author":"DW Howells","year":"2000","unstructured":"Howells, D. W. et al. Reduced BDNF mRNA expression in the Parkinson\u2019s disease substantia nigra. Exp. Neurol. 166, 127\u2013135 (2000).","journal-title":"Exp. Neurol."},{"key":"2840_CR282","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00415-009-5357-2","volume":"257","author":"P Scalzo","year":"2010","unstructured":"Scalzo, P., K\u00fcmmer, A., Bretas, T. L., Cardoso, F. & Teixeira, A. L. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson\u2019s disease. J. Neurol. 257, 540\u2013545 (2010).","journal-title":"J. Neurol."},{"key":"2840_CR283","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1073\/pnas.1713969114","volume":"114","author":"SS Kang","year":"2017","unstructured":"Kang, S. S. et al. TrkB neurotrophic activities are blocked by \u03b1-synuclein, triggering dopaminergic cell death in Parkinson\u2019s disease. Proc. Natl. Acad. Sci. USA 114, 10773\u201310778 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2840_CR284","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1523\/JNEUROSCI.1673-16.2016","volume":"37","author":"JJ Kopra","year":"2017","unstructured":"Kopra, J. J. et al. Dampened amphetamine-stimulated behavior and altered dopamine transporter function in the absence of brain GDNF. J. Neurosci. 37, 1581\u20131590 (2017).","journal-title":"J. Neurosci."},{"key":"2840_CR285","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.4103\/1673-5374.327330","volume":"17","author":"JA Conway","year":"2022","unstructured":"Conway, J. A. & Kramer, E. R. Is activation of GDNF\/RET signaling the answer for successful treatment of Parkinson\u2019s disease? A discussion of data from the culture dish to the clinic. Neural Regen Res. 17, 1462\u20131467 (2022).","journal-title":"Neural Regen Res."},{"key":"2840_CR286","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1093\/brain\/awr149","volume":"134","author":"M Decressac","year":"2011","unstructured":"Decressac, M. et al. GDNF fails to exert neuroprotection in a rat \u03b1-synuclein model of Parkinson\u2019s disease. Brain 134, 2302\u20132311 (2011).","journal-title":"Brain"},{"key":"2840_CR287","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/mds.28258","volume":"35","author":"P Chmielarz","year":"2020","unstructured":"Chmielarz, P. et al. GDNF\/RET signaling pathway activation eliminates lewy body pathology in midbrain dopamine neurons. Mov. Disord. 35, 2279\u20132289 (2020).","journal-title":"Mov. Disord."},{"key":"2840_CR288","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/brain\/awz023","volume":"142","author":"A Whone","year":"2019","unstructured":"Whone, A. et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson\u2019s disease. Brain 142, 512\u2013525 (2019).","journal-title":"Brain"},{"key":"2840_CR289","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown, R. H. & Al-Chalabi, A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 377, 162\u2013172 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR290","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","volume":"21","author":"JS Mora","year":"2020","unstructured":"Mora, J. S. et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph. Lateral Scler Frontotemporal Degener. 21, 5\u201314 (2020).","journal-title":"Amyotroph. Lateral Scler Frontotemporal Degener."},{"key":"2840_CR291","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/21678421.2016.1259334","volume":"18","author":"RL Sufit","year":"2017","unstructured":"Sufit, R. L., Ajroud-Driss, S., Casey, P. & Kessler, J. A. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler Frontotemporal Degener. 18, 269\u2013278 (2017).","journal-title":"Amyotroph. Lateral Scler Frontotemporal Degener."},{"key":"2840_CR292","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0620-9","volume":"13","author":"E Trias","year":"2016","unstructured":"Trias, E. et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflammation 13, 177 (2016).","journal-title":"J. Neuroinflammation"},{"key":"2840_CR293","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40478-021-01241-3","volume":"9","author":"M Kovacs","year":"2021","unstructured":"Kovacs, M. et al. The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS. Acta Neuropathol. Commun. 9, 136 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"2840_CR294","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104877","volume":"25","author":"C Dennys","year":"2022","unstructured":"Dennys, C. et al. EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis-astrocytes. iScience 25, 104877 (2022).","journal-title":"iScience"},{"key":"2840_CR295","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ajhg.2013.09.008","volume":"93","author":"Y Takahashi","year":"2013","unstructured":"Takahashi, Y. et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am. J. Hum. Genet. 93, 900\u2013905 (2013).","journal-title":"Am. J. Hum. Genet."},{"key":"2840_CR296","doi-asserted-by":"publisher","first-page":"122885","DOI":"10.1016\/j.jns.2024.122885","volume":"457","author":"Y Kwon","year":"2024","unstructured":"Kwon, Y. et al. Identification and characterization of novel ERBB4 variant associated with sporadic amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 457, 122885 (2024).","journal-title":"J. Neurol. Sci."},{"key":"2840_CR297","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s40200-025-01612-w","volume":"24","author":"A Amirabadizadeh","year":"2025","unstructured":"Amirabadizadeh, A. et al. Exploring the bidirectional association between thyrotropin and thyroid hormones in type 2 diabetes: a systematic review and meta-analysis. J. Diabetes Metab. Disord. 24, 98 (2025).","journal-title":"J. Diabetes Metab. Disord."},{"key":"2840_CR298","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837\u2013853 (1998).","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2840_CR299","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.tem.2015.09.003","volume":"26","author":"A Fountas","year":"2015","unstructured":"Fountas, A., Diamantopoulos, L. N. & Tsatsoulis, A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol. Metab. 26, 643\u2013656 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"2840_CR300","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","volume":"9","author":"SE Gitelman","year":"2021","unstructured":"Gitelman, S. E. et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 9, 502\u2013514 (2021).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2840_CR301","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41574-025-01114-y","volume":"21","author":"D Accili","year":"2025","unstructured":"Accili, D., Deng, Z. & Liu, Q. Insulin resistance in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 21, 413\u2013426 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2840_CR302","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.2337\/db12-0134","volume":"61","author":"J Agudo","year":"2012","unstructured":"Agudo, J. et al. Vascular endothelial growth factor-mediated islet hypervascularization and inflammation contribute to progressive reduction of \u03b2-cell mass. Diabetes 61, 2851\u20132861 (2012).","journal-title":"Diabetes"},{"key":"2840_CR303","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.diabres.2014.08.023","volume":"106","author":"E Mukai","year":"2014","unstructured":"Mukai, E. et al. Enhanced vascular endothelial growth factor signaling in islets contributes to \u03b2 cell injury and consequential diabetes in spontaneously diabetic Torii rats. Diabetes Res. Clin. Pract. 106, 303\u2013311 (2014).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2840_CR304","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.2337\/db12-1619","volume":"62","author":"SA Villalta","year":"2013","unstructured":"Villalta, S. A. et al. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes 62, 2870\u20132878 (2013).","journal-title":"Diabetes"},{"key":"2840_CR305","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0960-9822(03)00378-6","volume":"13","author":"E Lammert","year":"2003","unstructured":"Lammert, E. et al. Role of VEGF-A in vascularization of pancreatic islets. Curr. Biol. 13, 1070\u20131074 (2003).","journal-title":"Curr. Biol."},{"key":"2840_CR306","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.2337\/diabetes.51.7.2005","volume":"51","author":"SI Itani","year":"2002","unstructured":"Itani, S. I., Ruderman, N. B., Schmieder, F. & Boden, G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51, 2005\u20132011 (2002).","journal-title":"Diabetes"},{"key":"2840_CR307","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s42255-022-00634-5","volume":"4","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Insulin induces insulin receptor degradation in the liver through EphB4. Nat. Metab. 4, 1202\u20131213 (2022).","journal-title":"Nat. Metab."},{"key":"2840_CR308","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.2337\/db17-1513","volume":"67","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes. Diabetes 67, 1847\u20131857 (2018).","journal-title":"Diabetes"},{"key":"2840_CR309","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2337\/db17-1539","volume":"67","author":"A Abderrahmani","year":"2018","unstructured":"Abderrahmani, A. et al. Increased hepatic PDGF-AA signaling mediates liver insulin resistance in obesity-associated type 2 diabetes. Diabetes 67, 1310\u20131321 (2018).","journal-title":"Diabetes"},{"key":"2840_CR310","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.2337\/diabetes.53.11.2776","volume":"53","author":"T Yuasa","year":"2004","unstructured":"Yuasa, T. et al. Platelet-derived growth factor stimulates glucose transport in skeletal muscles of transgenic mice specifically expressing platelet-derived growth factor receptor in the muscle, but it does not affect blood glucose levels. Diabetes 53, 2776\u20132786 (2004).","journal-title":"Diabetes"},{"key":"2840_CR311","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/nm.2531","volume":"17","author":"A Fafalios","year":"2011","unstructured":"Fafalios, A. et al. A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat. Med. 17, 1577\u20131584 (2011).","journal-title":"Nat. Med."},{"key":"2840_CR312","doi-asserted-by":"publisher","first-page":"162ra153","DOI":"10.1126\/scitranslmed.3004690","volume":"4","author":"IN Foltz","year":"2012","unstructured":"Foltz, I. N. et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the \u03b2Klotho\/FGFR1c receptor complex. Sci. Transl. Med. 4, 162ra153 (2012).","journal-title":"Sci. Transl. Med."},{"key":"2840_CR313","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang, X. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57, 1246\u20131253 (2008).","journal-title":"Diabetes"},{"key":"2840_CR314","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1172\/JCI70710","volume":"123","author":"GJ Morton","year":"2013","unstructured":"Morton, G. J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Investig. 123, 4799\u20134808 (2013).","journal-title":"J. Clin. Investig."},{"key":"2840_CR315","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","volume":"143","author":"E Tomlinson","year":"2002","unstructured":"Tomlinson, E. et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143, 1741\u20131747 (2002).","journal-title":"Endocrinology"},{"key":"2840_CR316","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621\u20131624 (2011).","journal-title":"Science"},{"key":"2840_CR317","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000689","volume":"9","author":"J Li","year":"2025","unstructured":"Li, J. et al. The global prevalence and impact of steatotic liver disease and viral infections: a systematic review and meta-analysis. Hepatol. Commun. 9, e0689 (2025).","journal-title":"Hepatol. Commun."},{"key":"2840_CR318","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/hep.30696","volume":"70","author":"B Bhushan","year":"2019","unstructured":"Bhushan, B. et al. Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast-food diet model. Hepatology 70, 1546\u20131563 (2019).","journal-title":"Hepatology"},{"key":"2840_CR319","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1096\/fj.12-221812","volume":"27","author":"M Bagchi","year":"2013","unstructured":"Bagchi, M. et al. Vascular endothelial growth factor is important for brown adipose tissue development and maintenance. FASEB J 27, 3257\u20133271 (2013).","journal-title":"FASEB J"},{"key":"2840_CR320","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cmet.2019.11.013","volume":"31","author":"B Cai","year":"2020","unstructured":"Cai, B. et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metab. 31, 406\u2013421.e7 (2020).","journal-title":"Cell Metab."},{"key":"2840_CR321","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1124\/jpet.110.178046","volume":"337","author":"HR Lijnen","year":"2011","unstructured":"Lijnen, H. R., Christiaens, V. & Scroyen, L. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J. Pharmacol. Exp. Ther. 337, 457\u2013464 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2840_CR322","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jcmgh.2019.10.010","volume":"9","author":"A Tutusaus","year":"2020","unstructured":"Tutusaus, A. et al. A Functional Role of GAS6\/TAM in nonalcoholic steatohepatitis progression implicates AXL as therapeutic target. Cell. Mol. Gastroenterol. Hepatol. 9, 349\u2013368 (2020).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"2840_CR323","doi-asserted-by":"publisher","first-page":"G388","DOI":"10.1152\/ajpgi.00343.2017","volume":"314","author":"C Pridans","year":"2018","unstructured":"Pridans, C. et al. Macrophage colony-stimulating factor increases hepatic macrophage content, liver growth, and lipid accumulation in neonatal rats. Am. J. Physiol. Gastrointest. Liver Physiol. 314, G388\u2013G398 (2018).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2840_CR324","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1242\/dev.135962","volume":"144","author":"C Sun","year":"2017","unstructured":"Sun, C., Berry, W. L. & Olson, L. E. PDGFR\u03b1 controls the balance of stromal and adipogenic cells during adipose tissue organogenesis. Development 144, 83\u201394 (2017).","journal-title":"Development"},{"key":"2840_CR325","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1172\/JCI96324","volume":"127","author":"L Guo","year":"2017","unstructured":"Guo, L. et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J. Clin. Investig. 127, 4449\u20134461 (2017).","journal-title":"J. Clin. Investig."},{"key":"2840_CR326","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.molmet.2017.03.016","volume":"6","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders. Mol. Metab. 6, 863\u2013872 (2017).","journal-title":"Mol. Metab."},{"key":"2840_CR327","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.3713","volume":"20","author":"GX Wang","year":"2014","unstructured":"Wang, G. X. et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat. Med. 20, 1436\u20131443 (2014).","journal-title":"Nat. Med."},{"key":"2840_CR328","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1172\/JCI4433","volume":"103","author":"M Tahara","year":"1999","unstructured":"Tahara, M., Matsumoto, K., Nukiwa, T. & Nakamura, T. Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats. J. Clin. Investig. 103, 313\u2013320 (1999).","journal-title":"J. Clin. Investig."},{"key":"2840_CR329","doi-asserted-by":"publisher","first-page":"G204","DOI":"10.1152\/ajpgi.00021.2007","volume":"293","author":"T Kosone","year":"2007","unstructured":"Kosone, T. et al. HGF ameliorates a high-fat diet-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G204\u2013G210 (2007).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2840_CR330","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"JY Hsu","year":"2017","unstructured":"Hsu, J. Y. et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 550, 255\u2013259 (2017).","journal-title":"Nature"},{"key":"2840_CR331","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky, D. S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 19, 509\u2013524 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"2840_CR332","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","volume":"181","author":"L Fugger","year":"2020","unstructured":"Fugger, L., Jensen, L. T. & Rossjohn, J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell 181, 63\u201380 (2020).","journal-title":"Cell"},{"key":"2840_CR333","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","volume":"23","author":"F Ram\u00edrez-Valle","year":"2024","unstructured":"Ram\u00edrez-Valle, F., Maranville, J. C., Roy, S. & Plenge, R. M. Sequential immunotherapy: towards cures for autoimmunity. Nat. Rev. Drug Discov. 23, 501\u2013524 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2840_CR334","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"2840_CR335","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01133-0","volume":"21","author":"L Gao","year":"2023","unstructured":"Gao, L. et al. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis. Cell Commun. Signal. 21, 195 (2023).","journal-title":"Cell Commun. Signal."},{"key":"2840_CR336","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1756-185X.12367","volume":"20","author":"IH Bassyouni","year":"2017","unstructured":"Bassyouni, I. H., El-Wakd, M. M., Azab, N. A. & Bassyouni, R. H. Diminished soluble levels of growth arrest specific protein 6 and tyrosine kinase receptor Axl in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 20, 53\u201359 (2017).","journal-title":"Int. J. Rheum. Dis."},{"key":"2840_CR337","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15877","volume":"8","author":"M Kurowska-Stolarska","year":"2017","unstructured":"Kurowska-Stolarska, M. et al. MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nat. Commun. 8, 15877 (2017).","journal-title":"Nat. Commun."},{"key":"2840_CR338","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3389\/fimmu.2018.00742","volume":"9","author":"CEJ Waterborg","year":"2018","unstructured":"Waterborg, C. E. J. et al. Protective role of the MER tyrosine kinase via efferocytosis in rheumatoid arthritis models. Front. Immunol. 9, 742 (2018).","journal-title":"Front. Immunol."},{"key":"2840_CR339","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/annrheumdis-2012-202907","volume":"73","author":"G Ruiz-Heiland","year":"2014","unstructured":"Ruiz-Heiland, G. et al. Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. Ann. Rheum. Dis. 73, 771\u2013779 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"2840_CR340","doi-asserted-by":"publisher","first-page":"109753","DOI":"10.1016\/j.clim.2023.109753","volume":"255","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Tyro3 receptor tyrosine kinase contributes to pathogenic phenotypes of fibroblast-like synoviocytes in rheumatoid arthritis and disturbs immune cell balance in experimental arthritis. Clin. Immunol. 255, 109753 (2023).","journal-title":"Clin. Immunol."},{"key":"2840_CR341","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13075-020-02308-7","volume":"22","author":"J Xue","year":"2020","unstructured":"Xue, J. et al. CD14(+)CD16(-) monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK. Arthritis Res. Ther. 22, 221 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"2840_CR342","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.4049\/jimmunol.1500502","volume":"196","author":"M Charbonneau","year":"2016","unstructured":"Charbonneau, M. et al. Platelet-derived growth factor receptor activation promotes the prodestructive invadosome-forming phenotype of synoviocytes from patients with rheumatoid arthritis. J. Immunol. 196, 3264\u20133275 (2016).","journal-title":"J. Immunol."},{"key":"2840_CR343","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1136\/annrheumdis-2018-213498","volume":"77","author":"T Laragione","year":"2018","unstructured":"Laragione, T. et al. Huntingtin-interacting protein 1 (HIP1) regulates arthritis severity and synovial fibroblast invasiveness by altering PDGFR and Rac1 signalling. Ann. Rheum. Dis. 77, 1627\u20131635 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2840_CR344","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/ar2981","volume":"12","author":"S Rosengren","year":"2010","unstructured":"Rosengren, S., Corr, M. & Boyle, D. L. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res. Ther. 12, R65 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"2840_CR345","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1172\/JCI28546.","volume":"116","author":"RT Paniagua","year":"2006","unstructured":"Paniagua, R. T. et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Investig. 116, 2633\u20132642 (2006).","journal-title":"J. Clin. Investig."},{"key":"2840_CR346","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/RHU.0b013e318188b1ce","volume":"14","author":"KK Eklund","year":"2008","unstructured":"Eklund, K. K. et al. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J. Clin. Rheumatol. 14, 294\u2013296 (2008).","journal-title":"J. Clin. Rheumatol."},{"key":"2840_CR347","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/07853890310001339","volume":"35","author":"KK Eklund","year":"2003","unstructured":"Eklund, K. K. & Joensuu, H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann. Med. 35, 362\u2013367 (2003).","journal-title":"Ann. Med."},{"key":"2840_CR348","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10067-003-0716-3","volume":"22","author":"K Miyachi","year":"2003","unstructured":"Miyachi, K. et al. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin. Rheumatol. 22, 329\u2013332 (2003).","journal-title":"Clin. Rheumatol."},{"key":"2840_CR349","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR350","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/art.42858","volume":"76","author":"ESA Egal","year":"2024","unstructured":"Egal, E. S. A. et al. EphB2 receptor promotes dermal fibrosis in systemic sclerosis. Arthritis Rheumatol. 76, 1303\u20131316 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"2840_CR351","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000357806","volume":"228","author":"Z Gerlicz","year":"2014","unstructured":"Gerlicz, Z., Dziankowska-Bartkowiak, B., Dziankowska-Zaborszczyk, E. & Sysa-Jedrzejowska, A. Disturbed balance between serum levels of receptor tyrosine Kinases Tie-1, Tie-2 and angiopoietins in systemic sclerosis. Dermatology 228, 233\u2013239 (2014).","journal-title":"Dermatology"},{"key":"2840_CR352","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21249544","volume":"21","author":"T Carvalheiro","year":"2020","unstructured":"Carvalheiro, T. et al. Angiopoietin-2 promotes inflammatory activation in monocytes of systemic sclerosis patients. Int. J. Mol. Sci. 21, 1\u201310 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2840_CR353","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s10875-012-9743-7","volume":"32","author":"TA Gheita","year":"2012","unstructured":"Gheita, T. A., Bassyouni, I. H. & Bassyouni, R. H. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with Systemic lupus erythematosus and Beh\u00e7ets disease. J. Clin. Immunol. 32, 1279\u20131286 (2012).","journal-title":"J. Clin. Immunol."},{"key":"2840_CR354","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.coi.2010.10.001","volume":"22","author":"CV Rothlin","year":"2010","unstructured":"Rothlin, C. V. & Lemke, G. TAM receptor signaling and autoimmune disease. Curr. Opin. Immunol. 22, 740\u2013746 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"2840_CR355","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.jaut.2022.102861","volume":"132","author":"H Lou","year":"2022","unstructured":"Lou, H., Ling, G. S. & Cao, X. Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. J. Autoimmun. 132, 102861 (2022).","journal-title":"J. Autoimmun."},{"key":"2840_CR356","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel, C. H. & Sammaritano, L. R. Systemic lupus erythematosus: a review. JAMA 331, 1480\u20131491 (2024).","journal-title":"JAMA"},{"key":"2840_CR357","doi-asserted-by":"publisher","first-page":"132","DOI":"10.55563\/clinexprheumatol\/xyylza","volume":"39","author":"M Bellan","year":"2021","unstructured":"Bellan, M. et al. Increased plasma levels of Gas6 and its soluble tyrosine kinase receptors Mer and Axl are associated with immunological activity and severity of lupus nephritis. Clin. Exp. Rheumatol. 39, 132\u2013138 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2840_CR358","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13064","volume":"49","author":"S Gong","year":"2019","unstructured":"Gong, S. et al. Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis. Eur. J. Clin. Investig. 49, e13064 (2019).","journal-title":"Eur. J. Clin. Investig."},{"key":"2840_CR359","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. Nature 587, 555\u2013566 (2020).","journal-title":"Nature"},{"key":"2840_CR360","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633\u2013646 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2840_CR361","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.cmet.2020.10.026","volume":"33","author":"P Trivedi","year":"2021","unstructured":"Trivedi, P., Wang, S. & Friedman, S. L. The power of plasticity-metabolic regulation of hepatic stellate cells. Cell Metab. 33, 242\u2013257 (2021).","journal-title":"Cell Metab."},{"key":"2840_CR362","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2015.04.013","volume":"63","author":"C B\u00e1rcena","year":"2015","unstructured":"B\u00e1rcena, C. et al. Gas6\/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J. Hepatol. 63, 670\u2013678 (2015).","journal-title":"J. Hepatol."},{"key":"2840_CR363","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41420-023-01551-6","volume":"9","author":"K Staufer","year":"2023","unstructured":"Staufer, K. et al. Gas6 in chronic liver disease\u2014a novel blood-based biomarker for liver fibrosis. Cell Death Discov 9, 282 (2023).","journal-title":"Cell Death Discov"},{"key":"2840_CR364","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.jcmgh.2024.101380","volume":"18","author":"S Bano","year":"2024","unstructured":"Bano, S. et al. Hepatocyte-speciFic Epidermal Growth Factor Receptor Deletion Promotes Fibrosis But Has No Effect On Steatosis In Fast-food Diet Model Of Metabolic Dysfunction-associated Steatotic Liver Disease. Cell. Mol. Gastroenterol. Hepatol. 18, 101380 (2024).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"2840_CR365","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.med.55.091902.103810","volume":"55","author":"VJ Thannickal","year":"2004","unstructured":"Thannickal, V. J., Toews, G. B., White, E. S., Lynch, J. P. 3rd & Martinez, F. J. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 55, 395\u2013417 (2004).","journal-title":"Annu. Rev. Med."},{"key":"2840_CR366","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi, L., Collard, H. R. & Jones, M. G. Idiopathic pulmonary fibrosis. Lancet 389, 1941\u20131952 (2017).","journal-title":"Lancet"},{"key":"2840_CR367","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1164\/rccm.200603-333OC","volume":"174","author":"C Avivi-Green","year":"2006","unstructured":"Avivi-Green, C., Singal, M. & Vogel, W. F. Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 174, 420\u2013427 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2840_CR368","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1165\/rcmb.2017-0419OC","volume":"59","author":"S Jia","year":"2018","unstructured":"Jia, S. et al. Discoidin Domain Receptor 2 Signaling Regulates Fibroblast Apoptosis Through PDK1\/Akt. Am. J. Respir. Cell Mol. Biol. 59, 295\u2013305 (2018).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2840_CR369","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/mt.2016.109","volume":"24","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. Targeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis. Mol. Ther. 24, 1734\u20131744 (2016).","journal-title":"Mol. Ther."},{"key":"2840_CR370","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1298-1","volume":"15","author":"E Cherubini","year":"2017","unstructured":"Cherubini, E. et al. BDNF\/TrkB axis activation promotes epithelial-mesenchymal transition in idiopathic pulmonary fibrosis. J. Transl. Med. 15, 196 (2017).","journal-title":"J. Transl. Med."},{"key":"2840_CR371","doi-asserted-by":"publisher","first-page":"L360","DOI":"10.1152\/ajplung.00580.2016","volume":"313","author":"MR Freeman","year":"2017","unstructured":"Freeman, M. R. et al. Brain-derived neurotrophic factor and airway fibrosis in asthma. Am. J. Physiol. Lung Cell Mol. Physiol. 313, L360\u2013L370 (2017).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2840_CR372","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141061","volume":"6","author":"MS Hohmann","year":"2021","unstructured":"Hohmann, M. S. et al. Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF. JCI Insight 6, e141061 (2021).","journal-title":"JCI Insight"},{"key":"2840_CR373","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.intimp.2008.10.002","volume":"9","author":"XM Ou","year":"2009","unstructured":"Ou, X. M. et al. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int. Immunopharmacol. 9, 70\u201379 (2009).","journal-title":"Int. Immunopharmacol."},{"key":"2840_CR374","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071\u20132082 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR375","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1164\/rccm.201707-1519OC","volume":"197","author":"MS Espindola","year":"2018","unstructured":"Espindola, M. S. et al. Targeting of TAM receptors ameliorates fibrotic mechanisms in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 197, 1443\u20131456 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2840_CR376","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10565-024-09858-5","volume":"40","author":"YJ Lee","year":"2024","unstructured":"Lee, Y. J., Kim, M., Kim, H. S. & Kang, J. L. Administration of Gas6 attenuates lung fibrosis via inhibition of the epithelial-mesenchymal transition and fibroblast activation. Cell Biol. Toxicol. 40, 20 (2024).","journal-title":"Cell Biol. Toxicol."},{"key":"2840_CR377","doi-asserted-by":"publisher","first-page":"134786","DOI":"10.1016\/j.jhazmat.2024.134786","volume":"474","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Gas6-Axl signal promotes indoor VOCs exposure-induced pulmonary fibrosis via pulmonary microvascular endothelial cells-fibroblasts cross-talk. J. Hazard. Mater. 474, 134786 (2024).","journal-title":"J. Hazard. Mater."},{"key":"2840_CR378","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1165\/rcmb.2020-0303OC","volume":"64","author":"DC Yang","year":"2021","unstructured":"Yang, D. C. et al. Targeting the AXL receptor in combating smoking-related pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 64, 734\u2013746 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2840_CR379","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.addr.2021.03.021","volume":"173","author":"M Liu","year":"2021","unstructured":"Liu, M., L\u00f3pez de Juan Abad, B. & Cheng, K. Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies. Adv. Drug Deliv. Rev. 173, 504\u2013519 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2840_CR380","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","volume":"71","author":"P Kong","year":"2014","unstructured":"Kong, P., Christia, P. & Frangogiannis, N. G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 71, 549\u2013574 (2014).","journal-title":"Cell. Mol. Life Sci."},{"key":"2840_CR381","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1161\/HYPERTENSIONAHA.115.06254","volume":"67","author":"YF Zhao","year":"2016","unstructured":"Zhao, Y. F. et al. Growth arrest-specific 6 exacerbates pressure overload-induced cardiac hypertrophy. Hypertension 67, 118\u2013129 (2016).","journal-title":"Hypertension"},{"key":"2840_CR382","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yjmcc.2015.12.004","volume":"90","author":"M George","year":"2016","unstructured":"George, M., Vijayakumar, A., Dhanesh, S. B., James, J. & Shivakumar, K. Molecular basis and functional significance of Angiotensin II-induced increase in Discoidin Domain Receptor 2 gene expression in cardiac fibroblasts. J. Mol. Cell. Cardiol. 90, 59\u201369 (2016).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2840_CR383","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/ijms24010585","volume":"24","author":"AS Titus","year":"2023","unstructured":"Titus, A. S. et al. Metformin attenuates hyperglycaemia-stimulated pro-fibrotic gene expression in adventitial fibroblasts via inhibition of discoidin domain receptor 2. Int. J. Mol. Sci. 24, 585 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2840_CR384","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019904","volume":"10","author":"NW Chavkin","year":"2021","unstructured":"Chavkin, N. W. et al. The cell surface receptors Ror1\/2 control cardiac myofibroblast differentiation. J. Am. Heart Assoc. 10, e019904 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"2840_CR385","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1042\/CS20210644","volume":"135","author":"Z Huang","year":"2021","unstructured":"Huang, Z. et al. Key role for EphB2 receptor in kidney fibrosis. Clin. Sci. 135, 2127\u20132142 (2021).","journal-title":"Clin. Sci."},{"key":"2840_CR386","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150887","volume":"7","author":"CM Borza","year":"2022","unstructured":"Borza, C. M. et al. DDR1 contributes to kidney inflammation and fibrosis by promoting the phosphorylation of BCR and STAT3. JCI Insight 7, e150887 (2022).","journal-title":"JCI Insight"},{"key":"2840_CR387","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1681\/ASN.2006060677","volume":"17","author":"M Flamant","year":"2006","unstructured":"Flamant, M. et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J. Am. Soc. Nephrol. 17, 3374\u20133381 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2840_CR388","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0002-9440(10)65335-7","volume":"154","author":"H Yoshimoto","year":"1999","unstructured":"Yoshimoto, H. et al. Overexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts. Am. J. Pathol. 154, 883\u2013889 (1999).","journal-title":"Am. J. Pathol."},{"key":"2840_CR389","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s12325-024-03079-2","volume":"42","author":"Y Inoue","year":"2025","unstructured":"Inoue, Y. et al. Real-world safety, tolerability and effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis: final report of post-marketing surveillance in Japan. Adv. Ther. 42, 1075\u20131093 (2025).","journal-title":"Adv. Ther."},{"key":"2840_CR390","doi-asserted-by":"publisher","first-page":"10109","DOI":"10.1128\/JVI.01157-06","volume":"80","author":"M Shimojima","year":"2006","unstructured":"Shimojima, M. et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80, 10109\u201310116 (2006).","journal-title":"J. Virol."},{"key":"2840_CR391","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1126\/science.aaa3778","volume":"348","author":"E Bekerman","year":"2015","unstructured":"Bekerman, E. & Einav, S. Infectious disease. Combating emerging viral threats. Science 348, 282\u2013283 (2015).","journal-title":"Science"},{"key":"2840_CR392","doi-asserted-by":"publisher","first-page":"e1001099","DOI":"10.1371\/journal.ppat.1001099","volume":"6","author":"T Eierhoff","year":"2010","unstructured":"Eierhoff, T., Hrincius, E. R., Rescher, U., Ludwig, S. & Ehrhardt, C. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog. 6, e1001099 (2010).","journal-title":"PLoS Pathog."},{"key":"2840_CR393","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010874","volume":"18","author":"V Verma","year":"2022","unstructured":"Verma, V. et al. Influenza A virus activates cellular Tropomyosin receptor kinase A (TrkA) signaling to promote viral replication and lung inflammation. PLoS Pathog. 18, e1010874 (2022).","journal-title":"PLoS Pathog."},{"key":"2840_CR394","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1084\/jem.20121401","volume":"210","author":"IF Ueki","year":"2013","unstructured":"Ueki, I. F. et al. Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon \u03bb and antiviral defense in airway epithelium. J. Exp. Med. 210, 1929\u20131936 (2013).","journal-title":"J. Exp. Med."},{"key":"2840_CR395","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41392-024-01836-x","volume":"9","author":"HJ Shin","year":"2024","unstructured":"Shin, H. J. et al. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation. Signal Transduct. Target Ther. 9, 125 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2840_CR396","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41422-020-00460-y","volume":"31","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 31, 126\u2013140 (2021).","journal-title":"Cell Res."},{"key":"2840_CR397","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm.2341","volume":"17","author":"J Lupberger","year":"2011","unstructured":"Lupberger, J. et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17, 589\u2013595 (2011).","journal-title":"Nat. Med."},{"key":"2840_CR398","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrgastro.2011.89","volume":"8","author":"NJ Wood","year":"2011","unstructured":"Wood, N. J. Hepatitis C: Host receptor tyrosine kinases mediate HCV entry and are a promising new target for antiviral therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 361 (2011).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2840_CR399","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44960-6","volume":"15","author":"Q Pan","year":"2024","unstructured":"Pan, Q. et al. EGFR core fucosylation, induced by hepatitis C virus, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses. Nat. Commun. 15, 652 (2024).","journal-title":"Nat. Commun."},{"key":"2840_CR400","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000492","volume":"13","author":"A Saviano","year":"2022","unstructured":"Saviano, A. et al. Safety and antiviral activity of EGFR inhibition by erlotinib in chronic hepatitis C patients: a phase ib randomized controlled trial. Clin. Transl. Gastroenterol. 13, e00492 (2022).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"2840_CR401","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"S Jeon","year":"2020","unstructured":"Jeon, S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 64, e00819-20 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2840_CR402","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009275","volume":"17","author":"CM Stewart","year":"2021","unstructured":"Stewart, C. M. et al. Ebola virus triggers receptor tyrosine kinase-dependent signaling to promote the delivery of viral particles to entry-conducive intracellular compartments. PLoS Pathog. 17, e1009275 (2021).","journal-title":"PLoS Pathog."},{"key":"2840_CR403","first-page":"100720","volume":"5","author":"K Watanabe","year":"2024","unstructured":"Watanabe, K. et al. The whole picture of first-line osimertinib for EGFR mutation-positive advanced NSCLC: real-world efficacy, safety, progression pattern, and posttreatment therapy (Reiwa Study). JTO Clin. Res. Rep. 5, 100720 (2024).","journal-title":"JTO Clin. Res. Rep."},{"key":"2840_CR404","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0792-2","volume":"17","author":"WR Montor","year":"2018","unstructured":"Montor, W. R., Salas, A. & Melo, F. H. M. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Mol. Cancer 17, 55 (2018).","journal-title":"Mol. Cancer"},{"key":"2840_CR405","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1097\/JTO.0b013e318216ee52","volume":"6","author":"K Suda","year":"2011","unstructured":"Suda, K. et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 6, 1152\u20131161 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"2840_CR406","doi-asserted-by":"publisher","first-page":"101176","DOI":"10.1016\/j.drup.2024.101176","volume":"78","author":"D Wu","year":"2025","unstructured":"Wu, D. et al. Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies. Drug Resist. Updat. 78, 101176 (2025).","journal-title":"Drug Resist. Updat."},{"key":"2840_CR407","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano, G. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31, 171\u2013190 (2020).","journal-title":"Ann. Oncol."},{"key":"2840_CR408","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang, C. et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 20, 203\u2013222 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2840_CR409","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s10637-024-01476-6","volume":"42","author":"S Zhao","year":"2024","unstructured":"Zhao, S. et al. Clinical research progress of fruquintinib in the treatment of malignant tumors. Invest. New Drugs 42, 612\u2013622 (2024).","journal-title":"Invest. New Drugs"},{"key":"2840_CR410","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia, Y. et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534, 129\u2013132 (2016).","journal-title":"Nature"},{"key":"2840_CR411","doi-asserted-by":"publisher","first-page":"176484","DOI":"10.1016\/j.ejphar.2024.176484","volume":"970","author":"S Hussain","year":"2024","unstructured":"Hussain, S., Mursal, M., Verma, G., Hasan, S. M. & Khan, M. F. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors. Eur. J. Pharmacol. 970, 176484 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"2840_CR412","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","volume":"526","author":"J Golay","year":"2012","unstructured":"Golay, J. & Introna, M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch. Biochem. Biophys. 526, 146\u2013153 (2012).","journal-title":"Arch. Biochem. Biophys."},{"key":"2840_CR413","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/biom10030360","volume":"10","author":"H Shim","year":"2020","unstructured":"Shim, H. Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations. Biomolecules 10, 360 (2020).","journal-title":"Biomolecules"},{"key":"2840_CR414","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.gassur.2004.09.021","volume":"8","author":"JP Arnoletti","year":"2004","unstructured":"Arnoletti, J. P. et al. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J. Gastrointest. Surg. 8, 960\u2013969 (2004). discussion 969-970.","journal-title":"J. Gastrointest. Surg."},{"key":"2840_CR415","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","volume":"17","author":"H Li","year":"2020","unstructured":"Li, H., Er Saw, P. & Song, E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell. Mol. Immunol. 17, 451\u2013461 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"2840_CR416","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13046-016-0347-6","volume":"35","author":"L Feng","year":"2016","unstructured":"Feng, L. et al. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J. Exp. Clin. Cancer Res. 35, 70 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2840_CR417","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41401-024-01458-7","volume":"46","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Humanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity. Acta Pharmacol. Sin. 46, 1375\u20131389 (2025).","journal-title":"Acta Pharmacol. Sin."},{"key":"2840_CR418","doi-asserted-by":"publisher","first-page":"778978","DOI":"10.3389\/fimmu.2021.778978","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui, X. et al. A novel bispecific antibody targeting PD-L1 and VEGF with combined anti-tumor activities. Front. Immunol. 12, 778978 (2021).","journal-title":"Front. Immunol."},{"key":"2840_CR419","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway, J. B., Presta, L. G. & Carter, P. Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9, 617\u2013621 (1996).","journal-title":"Protein Eng"},{"key":"2840_CR420","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","volume":"108","author":"W Schaefer","year":"2011","unstructured":"Schaefer, W. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA 108, 11187\u201311192 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2840_CR421","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","volume":"32","author":"A Thakur","year":"2018","unstructured":"Thakur, A., Huang, M. & Lum, L. G. Bispecific antibody-based therapeutics: strengths and challenges. Blood Rev. 32, 339\u2013347 (2018).","journal-title":"Blood Rev."},{"key":"2840_CR422","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","volume":"10","author":"P Zhao","year":"2020","unstructured":"Zhao, P. et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm. Sin. B 10, 1589\u20131600 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"2840_CR423","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","volume":"64","author":"EL Sievers","year":"2013","unstructured":"Sievers, E. L. & Senter, P. D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15\u201329 (2013).","journal-title":"Annu. Rev. Med."},{"key":"2840_CR424","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","volume":"69","author":"JM Lambert","year":"2018","unstructured":"Lambert, J. M. & Berkenblit, A. Antibody-drug conjugates for cancer treatment. Annu. Rev. Med. 69, 191\u2013207 (2018).","journal-title":"Annu. Rev. Med."},{"key":"2840_CR425","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/jm500766w","volume":"57","author":"JM Lambert","year":"2014","unstructured":"Lambert, J. M. & Chari, R. V. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J. Med. Chem. 57, 6949\u20136964 (2014).","journal-title":"J. Med. Chem."},{"key":"2840_CR426","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR427","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J. Clin. 72, 165\u2013182 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"2840_CR428","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610\u2013621 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2840_CR429","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732\u2013742 (2017).","journal-title":"Lancet Oncol."},{"key":"2840_CR430","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100102","volume":"6","author":"F Schettini","year":"2021","unstructured":"Schettini, F. et al. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open 6, 100102 (2021).","journal-title":"ESMO Open"},{"key":"2840_CR431","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1158\/1535-7163.MCT-19-0022","volume":"18","author":"KA Whalen","year":"2019","unstructured":"Whalen, K. A. et al. Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer. Mol. Cancer Ther. 18, 1926\u20131936 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"2840_CR432","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1158\/1078-0432.CCR-20-3210","volume":"27","author":"A Cazes","year":"2021","unstructured":"Cazes, A. et al. A MET targeting antibody-drug conjugate overcomes gemcitabine resistance in pancreatic cancer. Clin. Cancer Res. 27, 2100\u20132110 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2840_CR433","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/1535-7163.MCT-21-0715","volume":"21","author":"F Zammarchi","year":"2022","unstructured":"Zammarchi, F. et al. Preclinical development of ADCT-601, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting AXL-expressing cancers. Mol. Cancer Ther. 21, 582\u2013593 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2840_CR434","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40425-019-0525-0","volume":"7","author":"HP Yao","year":"2019","unstructured":"Yao, H. P. et al. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt\/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. J. Immunother. Cancer 7, 75 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2840_CR435","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s40425-019-0732-8","volume":"7","author":"XM Tong","year":"2019","unstructured":"Tong, X. M. et al. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. J. Immunother. Cancer 7, 250 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2840_CR436","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","volume":"23","author":"P Flynn","year":"2024","unstructured":"Flynn, P., Suryaprakash, S., Grossman, D., Panier, V. & Wu, J. The antibody-drug conjugate landscape. Nat. Rev. Drug Discov. 23, 577\u2013578 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2840_CR437","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa, K. et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655\u20131669 (2019).","journal-title":"Lancet Oncol."},{"key":"2840_CR438","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","volume":"15","author":"GN Naumov","year":"2009","unstructured":"Naumov, G. N. et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 15, 3484\u20133494 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2840_CR439","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","volume":"20","author":"RJ Motzer","year":"2022","unstructured":"Motzer, R. J. et al. Kidney Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 20, 71\u201390 (2022).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"2840_CR440","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","volume":"5","author":"MA Gorin","year":"2022","unstructured":"Gorin, M. A. et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur. Urol. Oncol. 5, 113\u2013117 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"2840_CR441","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","volume":"81","author":"MI Carlo","year":"2022","unstructured":"Carlo, M. I. et al. Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy. Eur. Urol. 81, 570\u2013573 (2022).","journal-title":"Eur. Urol."},{"key":"2840_CR442","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2022.40.6_suppl.289","volume":"40","author":"A Bex","year":"2022","unstructured":"Bex, A. et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). J. Clin. Oncol. 40, 289\u2013289 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2840_CR443","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008475","volume":"12","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial. J. Immunother. Cancer 12, e008475 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2840_CR444","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","volume":"4","author":"CK Lee","year":"2018","unstructured":"Lee, C. K. et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol 4, 210\u2013216 (2018).","journal-title":"JAMA Oncol"},{"key":"2840_CR445","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.23.02747","volume":"42","author":"JC Yang","year":"2024","unstructured":"Yang, J. C. et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J. Clin. Oncol. 42, 4029\u20134039 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2840_CR446","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","volume":"30","author":"Y Malam","year":"2009","unstructured":"Malam, Y., Loizidou, M. & Seifalian, A. M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30, 592\u2013599 (2009).","journal-title":"Trends Pharmacol. Sci."},{"key":"2840_CR447","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jconrel.2024.05.005","volume":"371","author":"CA Juul","year":"2024","unstructured":"Juul, C. A. et al. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model. J. Control. Release 371, 288\u2013297 (2024).","journal-title":"J. Control. Release"},{"key":"2840_CR448","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302187","volume":"12","author":"J Zhang","year":"2023","unstructured":"Zhang, J., Li, X., Yin, Y., Cao, G. & Wang, H. A Biodegradable nucleotide coordination polymer for enhanced NSCLC therapy in combination with metabolic modulation. Adv. Healthc. Mater. 12, e2302187 (2023).","journal-title":"Adv. Healthc. Mater."},{"key":"2840_CR449","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1200\/JCO.2018.36.15_suppl.3046","volume":"36","author":"S Papa","year":"2018","unstructured":"Papa, S. et al. A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC). J. Clin. Oncol. 36, 3046\u20133046 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2840_CR450","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11427-018-9451-0","volume":"62","author":"C Lin","year":"2019","unstructured":"Lin, C. & Zhang, J. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy. Sci China Life Sci. 62, 633\u2013639 (2019).","journal-title":"Sci China Life Sci."},{"key":"2840_CR451","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy 22, 573\u2013580 (2020).","journal-title":"Cytotherapy"},{"key":"2840_CR452","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"2840_CR453","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","volume":"31","author":"CA Jaeger-Ruckstuhl","year":"2025","unstructured":"Jaeger-Ruckstuhl, C. A. et al. Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies. Clin. Cancer Res. 31, 503\u2013514 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2840_CR454","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","volume":"13","author":"HS Budi","year":"2022","unstructured":"Budi, H. S. et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress. Stem Cell Res. Ther. 13, 40 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"2840_CR455","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2127508","volume":"11","author":"MI Strecker","year":"2022","unstructured":"Strecker, M. I. et al. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. Oncoimmunology 11, 2127508 (2022).","journal-title":"Oncoimmunology"},{"key":"2840_CR456","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","volume":"81","author":"R Ma","year":"2021","unstructured":"Ma, R. et al. An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma. Cancer Res. 81, 3635\u20133648 (2021).","journal-title":"Cancer Res."},{"key":"2840_CR457","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","volume":"363","author":"B Tao","year":"2023","unstructured":"Tao, B. et al. Engineering CAR-NK cell-derived exosome disguised nano-bombs for enhanced HER2-positive breast cancer brain metastasis therapy. J. Control. Release 363, 692\u2013706 (2023).","journal-title":"J. Control. Release"},{"key":"2840_CR458","doi-asserted-by":"publisher","first-page":"114113","DOI":"10.1016\/j.addr.2022.114113","volume":"182","author":"G Kara","year":"2022","unstructured":"Kara, G., Calin, G. A. & Ozpolat, B. RNAi-based therapeutics and tumor-targeted delivery in cancer. Adv. Drug Deliv. Rev. 182, 114113 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2840_CR459","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature02873","volume":"431","author":"G Meister","year":"2004","unstructured":"Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343\u2013349 (2004).","journal-title":"Nature"},{"key":"2840_CR460","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","volume":"65","author":"CN Landen Jr.","year":"2005","unstructured":"Landen, C. N. Jr. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910\u20136918 (2005).","journal-title":"Cancer Res."},{"key":"2840_CR461","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ajo.2010.02.006","volume":"150","author":"PK Kaiser","year":"2010","unstructured":"Kaiser, P. K. et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am. J. Ophthalmol. 150, 33\u201339.e32 (2010).","journal-title":"Am. J. Ophthalmol."},{"key":"2840_CR462","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","volume":"59","author":"L Aagaard","year":"2007","unstructured":"Aagaard, L. & Rossi, J. J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59, 75\u201386 (2007).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2840_CR463","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nbt831","volume":"21","author":"AL Jackson","year":"2003","unstructured":"Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635\u2013637 (2003).","journal-title":"Nat. Biotechnol."},{"key":"2840_CR464","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nbt.3026","volume":"32","author":"JG Doench","year":"2014","unstructured":"Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262\u20131267 (2014).","journal-title":"Nat. Biotechnol."},{"key":"2840_CR465","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.molmed.2019.07.007","volume":"25","author":"C Jiang","year":"2019","unstructured":"Jiang, C., Lin, X. & Zhao, Z. Applications of CRISPR\/Cas9 technology in the treatment of lung cancer. Trends Mol. Med. 25, 1039\u20131049 (2019).","journal-title":"Trends Mol. Med."},{"key":"2840_CR466","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1093\/nar\/gkx490","volume":"45","author":"T Koo","year":"2017","unstructured":"Koo, T. et al. Selective disruption of an oncogenic mutant allele by CRISPR\/Cas9 induces efficient tumor regression. Nucleic Acids Res. 45, 7897\u20137908 (2017).","journal-title":"Nucleic Acids Res."},{"key":"2840_CR467","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai, J. M., Nowak, R. P., Ebert, B. L. & Fischer, E. S. Targeted protein degradation: from mechanisms to clinic. Nat. Rev. Mol. Cell Biol. 25, 740\u2013757 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2840_CR468","doi-asserted-by":"publisher","first-page":"100647","DOI":"10.1016\/j.jbc.2021.100647","volume":"296","author":"SB Alabi","year":"2021","unstructured":"Alabi, S. B. & Crews, C. M. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J. Biol. Chem. 296, 100647 (2021).","journal-title":"J. Biol. Chem."},{"key":"2840_CR469","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67\u201377.e63 (2018).","journal-title":"Cell Chem. Biol."},{"key":"2840_CR470","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","volume":"61","author":"CE Powell","year":"2018","unstructured":"Powell, C. E. et al. Chemically induced degradation of anaplastic lymphoma kinase (ALK). J. Med. Chem. 61, 4249\u20134255 (2018).","journal-title":"J. Med. Chem."},{"key":"2840_CR471","doi-asserted-by":"publisher","first-page":"114533","DOI":"10.1016\/j.ejmech.2022.114533","volume":"239","author":"D Hong","year":"2022","unstructured":"Hong, D. et al. Recent advances in the development of EGFR degraders: PROTACs and LYTACs. Eur. J. Med. Chem. 239, 114533 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"2840_CR472","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41388-024-03241-8","volume":"44","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Discovery of a molecular glue for EGFR degradation. Oncogene 44, 545\u2013556 (2025).","journal-title":"Oncogene"},{"key":"2840_CR473","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik, S. M. et al. Lysosome-targeting chimeras for degradation of extracellular proteins. Nature 584, 291\u2013297 (2020).","journal-title":"Nature"},{"key":"2840_CR474","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09358-9","volume":"10","author":"KR Simonetta","year":"2019","unstructured":"Simonetta, K. R. et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat. Commun. 10, 1402 (2019).","journal-title":"Nat. Commun."},{"key":"2840_CR475","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.03385","volume":"3","author":"ED Lew","year":"2014","unstructured":"Lew, E. D. et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. eLife 3, e03385 (2014).","journal-title":"eLife"},{"key":"2840_CR476","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","volume":"75","author":"A Kirane","year":"2015","unstructured":"Kirane, A. et al. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Res. 75, 3699\u20133705 (2015).","journal-title":"Cancer Res."},{"key":"2840_CR477","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature12998","volume":"507","author":"M Paolino","year":"2014","unstructured":"Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508\u2013512 (2014).","journal-title":"Nature"},{"key":"2840_CR478","doi-asserted-by":"publisher","first-page":"25750","DOI":"10.1074\/jbc.M114.569020","volume":"289","author":"WI Tsou","year":"2014","unstructured":"Tsou, W. I. et al. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J. Biol. Chem. 289, 25750\u201325763 (2014).","journal-title":"J. Biol. Chem."},{"key":"2840_CR479","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J. et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"2840_CR480","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nchembio.1636","volume":"10","author":"MS Kariolis","year":"2014","unstructured":"Kariolis, M. S. et al. An engineered Axl \u2018decoy receptor\u2019 effectively silences the Gas6-Axl signaling axis. Nat. Chem. Biol. 10, 977\u2013983 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"2840_CR481","doi-asserted-by":"publisher","first-page":"178ra139","DOI":"10.1126\/scitranslmed.3005414","volume":"5","author":"TC Harding","year":"2013","unstructured":"Harding, T. C. et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 5, 178ra139 (2013).","journal-title":"Sci. Transl. Med."},{"key":"2840_CR482","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero, J. et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406\u2013417 (2013).","journal-title":"Cancer Discov."},{"key":"2840_CR483","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-20-2811","volume":"81","author":"Y Kashima","year":"2021","unstructured":"Kashima, Y. et al. Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Res 81, 4835\u20134848 (2021).","journal-title":"Cancer Res"},{"key":"2840_CR484","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06940-y","volume":"15","author":"M Izumi","year":"2024","unstructured":"Izumi, M. et al. Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. Cell Death Dis 15, 580 (2024).","journal-title":"Cell Death Dis"},{"key":"2840_CR485","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11729-1","volume":"10","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4\/6 inhibitor-resistant HER2-positive breast cancer. Nat. Commun. 10, 3817 (2019).","journal-title":"Nat. Commun."},{"key":"2840_CR486","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.annonc.2022.01.004","volume":"33","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. Ann. Oncol. 33, 434\u2013444 (2022).","journal-title":"Ann. Oncol."},{"key":"2840_CR487","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl2528","volume":"384","author":"R Krishna","year":"2024","unstructured":"Krishna, R. et al. Generalized biomolecular modeling and design with RoseTTAFold All-Atom. Science 384, eadl2528 (2024).","journal-title":"Science"},{"key":"2840_CR488","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"2840_CR489","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41592-020-0848-2","volume":"17","author":"JK Leman","year":"2020","unstructured":"Leman, J. K. et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat. Methods 17, 665\u2013680 (2020).","journal-title":"Nat. Methods"},{"key":"2840_CR490","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41568-018-0104-6","volume":"19","author":"A Sontheimer-Phelps","year":"2019","unstructured":"Sontheimer-Phelps, A., Hassell, B. A. & Ingber, D. E. Modelling cancer in microfluidic human organs-on-chips. Nat. Rev. Cancer 19, 65\u201381 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2840_CR491","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","volume":"9","author":"M Shibuya","year":"2006","unstructured":"Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9, 225\u2013230 (2006).","journal-title":"Angiogenesis"},{"key":"2840_CR492","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/13543784.2019.1667333","volume":"28","author":"RM Hussain","year":"2019","unstructured":"Hussain, R. M., Neiweem, A. E., Kansara, V., Harris, A. & Ciulla, T. A. Tie-2\/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin. Investig. Drugs 28, 861\u2013869 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2840_CR493","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicolo","year":"2021","unstructured":"Nicolo, M., Ferro Desideri, L., Vagge, A. & Traverso, C. E. Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin. Investig. Drugs 30, 193\u2013200 (2021).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2840_CR494","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.nbd.2018.12.021","volume":"124","author":"I Lopez-Font","year":"2019","unstructured":"Lopez-Font, I. et al. Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiol. Dis. 124, 428\u2013438 (2019).","journal-title":"Neurobiol. Dis."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02840-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02840-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02840-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T23:02:03Z","timestamp":1791759723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02840-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":494,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2840"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02840-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"440"}}